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ABSTRACT OF DISSERTATION

ENTRY AND REPLICATION OF NEGATIVE-STRAND RNA VIRUSES
Hendra virus (HeV) and human metapneumovirus (HMPV) are negativesense, singled-stranded RNA viruses. The paramyxovirus HeV is classified as a
biosafety level 4 pathogen due to its high fatality rate and the lack of a human
vaccine or antiviral treatment. HMPV is a widespread pneumovirus that causes
respiratory tract infections which are particularly dangerous for young children,
immunocompromised individuals, and the elderly. Like HeV, no vaccines or
therapies are available to combat HMPV infections. These viruses fuse their lipid
envelopes with a cell to initiate infection. Blocking cell entry is a promising
approach for antiviral development, and many vaccines are designed based on the
envelope protein responsible for fusion. Following fusion, the coated genome and
its associated proteins are released into the cytoplasm for replication and
transcription. HMPV and other negative-strand viruses form membrane-less
inclusion bodies (IBs) which act as viral factories to promote these processes.
HMPV IBs represent another promising target for developing new antivirals since
they house the replication machinery. Viral fusion and cytoplasmic replication are
ubiquitous to most negative-strand viruses and are addressed in this work through
analysis of HeV and HMPV.
HeV utilizes a trimeric fusion protein (F) within its lipid bilayer to mediate
membrane merger with a cell for entry. Previous HeV F studies showed that
transmembrane domain (TMD) interactions are important for stabilizing the
prefusion conformation of the protein prior to triggering. Thus, the current model
for HeV F fusion suggests that modulation of TMD interactions is critical for
initiation and completion of conformational changes that drive membrane fusion.
HeV F constructs (T483C/V484C, V484C/N485C, and N485C/P486C) were
generated with double cysteine substitutions near the N-terminal region of the TMD
to study the effect of altered flexibility in this region. Oligomeric analysis showed
that the double cysteine substitutions successfully promoted intersubunit disulfide
bond formation in HeV F. Subsequent fusion assays indicated that the introduction
of disulfide bonds in the mutants prohibited fusion events, likely due to the limited
flexibility in the TMD. Further testing confirmed that T483C/V484C and
V484C/N485C were expressed at the cell surface at levels that would allow for
fusion. Attempts to restore fusion with a reducing agent were unsuccessful,
suggesting that the introduced disulfide bonds were likely buried in the membrane.
Conformational analysis showed that T483C/V484C and V484C/N485C were able

to bind a prefusion conformation-specific antibody prior to cell disruption, indicating
that the introduced disulfide bonds did not significantly affect protein folding. This
study strengthens the current model for HeV fusion and provides important insight
for understanding the basic mechanisms of membrane fusion for negative-strand
RNA viruses.
HMPV IBs are dynamic structures required for efficient replication and
transcription. The minimum components needed to form IB-like structures in cells
are the nucleoprotein (N), which coats the RNA genome, and the tetrameric
phosphoprotein (P), which acts as a cofactor to the polymerase. HMPV P binds to
two versions of N protein in infected cells: C-terminal P residues interact with
oligomeric, RNA-bound N (N-RNA), and N-terminal P residues interact with
monomeric N (N0) to maintain a pool of protein to encapsidate new RNA. Recent
work on other negative-strand viruses has shown that IBs are liquid-like organelles
formed via liquid-liquid phase separation (LLPS). Recombinant versions of HMPV
N and P proteins were purified to analyze the interactions required to drive LLPS
in vitro. Purified HMPV P was shown to form liquid droplets in the absence of other
protein binding partners, suggesting that it functions as a scaffold to recruit client
proteins to IBs. HMPV P recruited a monomeric N protein construct, N0-P, to liquid
droplets. In addition, HMPV P incorporated N-RNA into liquid droplets, though NRNA formed aggregates independently. These findings support that HMPV P acts
as a scaffold protein to mediate multivalent interactions with monomeric and
oligomeric HMPV N to promote phase separation of IBs. Collectively, the work
presented here provides important insight into the processes of viral entry,
replication, and IB formation for negative-strand RNA viruses.
KEYWORDS: Paramyxovirus, Membrane Fusion, Phase Separation, Human
Metapneumovirus, Viral Replication, Inclusion Body
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Chapter 1: Background and Introduction
The Mononegavirales order
The Mononegavirales order was created in 1991 to classify three families
of viruses. As of 2018, the order now includes eight families: Bornaviridae,
Filoviridae, Mymonaviridae, Nyamiviridae, Paramyxoviridae, Pneumoviridae,
Rhabdoviridae, and Sunviridae (1). Four of these families are recognized for their
role in human disease: Filoviridae, Paramyxoviridae, Pneumoviridae, and
Rhabdoviridae (2). All viruses within these families possess a lipid bilayer envelope
that is derived from the host cell. The envelope includes membrane glycoproteins
that are responsible for binding to a cell and fusing the envelope with the target
cell membrane. Fusion of the membranes allows for the release of the viral
genome and its associated proteins into the cell cytoplasm. The Mononegavirales
viruses possess nonsegmented genomes, meaning that the genetic material is
included on one strand of nucleic acid. Additionally, the genomes are made of
negative-sense RNA, so the viruses must deliver the genome with proteins needed
for replication and transcription into the target cell to initiate infection (1). The
genome is flanked by a 3’ leader sequence and 5’ trailer sequence that help
regulate replication and transcription. Five to ten genes are encoded by the
genome, and transcription of the genes generates viral mRNAs that are capped
and polyadenylated. The viral mRNAs are translated and the genome is replicated
so that new viral particles can be assembled and released, often through budding
events at the cell plasma membrane. The results reported in later chapters of this
dissertation describe viruses from the Paramyxoviridae and Pneumoviridae
families. Specifically, this work focuses on fusion events related to viral entry and
mechanisms involved in viral replication. Though this work analyzes two viruses to
explore these life cycle steps, the findings are applicable to many viruses
throughout the Mononegavirales order. Understanding basic mechanisms in the
life cycle of negative-sense, single-stranded RNA viruses is critical for the
development of vaccines and antivirals to combat human disease.
1

Paramyxoviruses
The Paramyxoviridae family contains numerous members, including
several human pathogens of medical significance, such as measles virus (MeV),
mumps virus (MuV), and the parainfluenza viruses (PIVs). The family also includes
the zoonotic pathogens Hendra virus (HeV) and Nipah virus (NiV) which were
discovered in 1994 and 1999, respectively, after spillovers occurred in humans (3).
Members of the Paramyxoviridae family such as Sendai virus and Newcastle
disease virus are known to infect other animal species (4). Viruses within this
family transmit via a horizontal pathway, meaning that they spread between
members of the same generation rather than from mother to offspring, and they
typically utilize airborne routes (5).
Paramyxovirus particles are generally 150 to 500 nm in diameter, and they
are pleomorphic, though most have a spherical shape (5). The viral lipid bilayer
encloses the RNA genome which is coated in nucleoprotein (N) to form a helical
nucleocapsid. Genomes for paramyxoviruses range from 15 to 19 kilobases. The
genome codes for six to ten gene products, including two transmembrane
glycoproteins found in the viral lipid bilayer. These transmembrane proteins allow
the virus to attach and fuse with target cells to initiate the viral life cycle (4). Some
paramyxoviruses also encode a third membrane protein known as the small
hydrophobic protein (SH), but the function of this protein is less clear. The SH
protein is reported to inhibit TNF-alpha signaling for two rubulaviruses within the
Paramyxoviridae family (6). Once the virus fuses with a target cell, transcription of
the genome occurs in the cytoplasm. The viral phosphoprotein (P) and RNAdependent RNA polymerase use the N-encapsidated, negative-sense genome as
a template to encode mRNAs that are translated by host cell machinery to produce
viral proteins. Additionally, the negative-sense RNA genome is used as a template
to produce positive-sense antigenome. In turn, the positive-sense antigenome is
replicated to make negative-sense genomic copies that are coated in N protein
and transported to the plasma membrane for assembly with other viral
components, followed by budding of nascent virions (5).
2

Hendra virus
HeV was identified in 1994 after an outbreak in Brisbane, Australia that led
to the death of 14 horses and one human (7, 8). Horses infected with HeV typically
experience acute respiratory symptoms and high fevers (9). In humans, HeV
causes flu-like respiratory symptoms that can progress to severe pneumonia, and
infection is also associated with encephalitis, leading to symptoms such as
confusion and headaches (7, 10). All human cases of HeV have been linked to
close contact with infected horses (11). The initial outbreak and subsequent cases
in Australia culminated in an 89 percent fatality rate in horses and a 57 percent
fatality rate in humans (10). Since HeV is designated as a biosafety level 4
pathogen, work with live HeV is restricted to specialized biocontainment facilities
(12). The life cycle of HeV initiates with an attachment and fusion event, in which
the viral membrane merges with the target cell membrane (FIG 1.1). The coated
genome is released into the target cell where it undergoes replication and
transcription in the cytoplasm. The viral mRNAs are translated into protein and
assembled with newly synthesized viral genome at the cell surface. The virus
acquires its membrane, studded with viral proteins, from the host as it buds from
the surface.
Further research into the causes of the HeV outbreak led to the identification
of Australian flying fox fruit bats of the Pteropus genus as the natural reservoir for
the zoonotic virus. These bats are nocturnal foragers, and they are abundant in
urban areas within eastern Australia where they find reliable food sources (9). The
four flying fox species of bats native to Australia are all seropositive for HeV
antibodies (12). A model was proposed that horses were exposed to HeV by eating
fruit contaminated with infected bat urine (10). Horse-to-horse transmission of
infection has been observed in subsequent outbreaks (9). Horses have served as
an intermediate host to amplify the virus and pass the infection to humans. Though
a horse vaccine against HeV became available in 2012, there are currently no
approved vaccines or treatments to protect humans (11).
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HeV is closely related to the paramyxovirus NiV, which caused an outbreak
of encephalitic disease in Malaysia in 1999. During the outbreak, 265 encephalitic
cases were confirmed in patients, and 105 deaths were reported, leading to a
fatality rate of approximately 40 percent (13). Since the zoonotic HeV and NiV
showed many differences from other members of the Paramyxoviridae family, the
Henipavirus genus was created in 2000 to categorize these pathogens (1).
Research into the source of the NiV outbreak showed that the virus was
transmitted from bats to pigs before spilling into humans (3). Deadly NiV outbreaks
have also occurred in Bangladesh, Singapore, and India. Additionally, human-tohuman transmission of NiV was observed in Bangladesh and India (14). Like HeV,
there are no approved vaccines or therapies to combat future NiV disease
outbreaks in humans.
Scientists have also discovered a non-pathogenic henipavirus, known as
Cedar virus (CedPV), which was isolated from the urine of Australian fruit bats
(15). Since studies of HeV and NiV are limited due to their biosafety classification,
research on live CedPV will be beneficial for elucidating the infectious mechanisms
of henipaviruses. The current COVID-19 pandemic highlights the importance of
studying the life cycle of emergent respiratory pathogens like HeV and NiV. Severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID19, is a positive-strand RNA virus with a genome of approximately 30 kilobases.
Some coronavirus replication complexes have been shown to possess
proofreading ability, which is important for controlling the mutation rate during
replication of the large RNA genomes (16). When mutations do occur, they may
increase the likelihood of spillover into a different species. Like HeV and NiV,
SARS-CoV-2 is a zoonotic virus that is thought to have originated in bats before
spilling into humans, and it primarily transmits via respiratory droplets (17). The
high quantity of asymptomatic SARS-CoV-2 infections has contributed to the
worldwide spread of disease. Although the henipaviruses and coronaviruses are
categorized within different phylogenetic orders, similarities in their origin and
transmission routes suggest that further research is needed to analyze the
emergence of respiratory pathogens. Understanding the processes by which HeV
4

and NiV initiate infection, replicate, and spread may contribute to discoveries to
prevent widespread outbreaks of newly emerged RNA viruses. Specifically,
research into HeV fusion events is critical for the development of novel therapies
and vaccines that may protect human populations from deadly infections.
Paramyxovirus surface glycoproteins
Paramyxoviruses possess attachment proteins (H, HN, or G) and fusion
proteins (F) that are located on the surface of the virus. The attachment proteins
are homotetrameric type II integral membrane proteins that bind to specific
receptors on target cells (4). They consist of a globular receptor binding domain
and a membrane proximal stalk. Paramyxoviruses with HN attachment proteins
bind to sialic acid and possess a neuraminidase function (4). The morbilliviruses
within the Paramyxoviridae family use the attachment protein H, which binds sialic
acid but does not have neuraminidase activity. Interestingly, the G protein of
henipaviruses is unable to bind or cleave sialic acid. Instead, it interacts with the
protein receptor Ephrin B2 or Ephrin B3 to promote close contact between the viral
and cellular membranes for fusion events (4). Along with mediating initial binding
events with a cell, paramyxovirus attachment proteins are reported to have fusionpromoting functions, since co-expression of both the attachment and fusion protein
is required for viral spread (4). Some studies have suggested that the attachment
protein and F protein must physically interact to promote membrane fusion (18).
However, the mechanisms that regulate this attachment protein-dependent
triggering are not fully understood.
Paramyxoviruses express homotrimeric type I F proteins that undergo
irreversible conformational changes to mediate membrane fusion events between
the virus and a cell. Domains of the protein include a hydrophobic fusion peptide
(FP), two heptad repeat regions (HRA and HRB), a single-pass transmembrane
domain (TMD), and a C-terminal cytoplasmic tail (CT). The F protein is synthesized
at the endoplasmic reticulum (ER) in an inactive precursor form (F0). During
translation, the protein inserts into the ER membrane and folds into its trimeric
structure. Proper folding of the F protein is essential for its triggering function which
5

requires dynamic conformational changes. The newly synthesized F0 must
undergo proteolytic cleavage to generate the metastable prefusion form (F1+F2)
that is capable of mediating fusion events once triggered. Proteolytic cleavage of
F0 yields the disulfide-linked heterodimer F1+F2 which helps to properly position
the FP and may lower the energy barrier for F protein triggering (FIG 1.2) (4). The
F protein must also undergo glycosylation. Though all paramyxovirus F proteins
are glycosylated, the glycosylation sites vary depending on the virus. For HeV F,
four glycosylation sites were shown to be required for proper folding and fusion.
Two of these glycosylation sites are present in the F2 subunit (N67 and N69) and
two are present in the F1 subunit (N414 and N464) (19).
Proteolytic cleavage of the F protein is an essential step for all
paramyxoviruses. Without this step, the F protein is maintained in an inactive form
that prohibits the virus from fusing with target cells to initiate infection. The
pathways and proteases utilized to process F0 to generate F1+F2 vary amongst the
paramyxoviruses. Many paramyxovirus F proteins are processed by the protease
furin as they are transported through the trans-Golgi network to reach the cell
plasma membrane (20). The furin enzyme belongs to the subtilisin-like proprotein
convertase family and is enriched in the Golgi apparatus. It recognizes the
sequence R-X-K/R-R and cleaves proteins to generate their mature or active form.
This F protein proteolytic cleavage pathway is used by paramyxoviruses such as
PIV5 and MeV (21, 22). Neither HeV F nor NiV F contains the furin recognition
sequence. Instead, these henipaviruses have been shown to utilize the cellular
protease cathepsin L to generate the metastable F1+F2 heterodimer (23-25).
Cathepsin L is an endosomal/lysosomal protease that is typically recognized for
its role in destruction of intracellular and endocytosed proteins. Both HeV F and
NiV F possess endocytosis motifs within their CTs and trafficking signals in their
TMDs (26-28). After trafficking to the plasma membrane, the CT motifs signal for
the F proteins to be endocytosed. The F proteins are processed by cathepsin L in
a pH-dependent manner within recycling endosomes before being trafficked back
to the cell surface where they can participate in fusion events (FIG 1.3).

6

To mediate fusion, the paramyxovirus F protein must overcome the
energetically unfavorable process of merging two lipid bilayers. The F protein
provides the energy required for this process by refolding from its metastable
conformation into a stable, low energy, postfusion state. After the G protein binds
to the target cell receptor, interactions between the F and G proteins are thought
to trigger conformational changes in the F protein for fusion, and different models
have been suggested for these interactions. The “clamp” model suggests that the
F and G proteins form a complex that is trafficked to the cell surface, allowing the
G protein to stabilize the F protein in its metastable state. Upon receptor binding,
the F protein dissociates from the G protein to undergo refolding events. In the
“association” model, the G protein is not required to stabilize the F protein
prefusion state. Rather, the G protein binds to its receptor and then interacts with
the F protein in a manner that destabilizes the prefusion form to promote fusion
(18). Once triggered, the hydrophobic FP of the F protein is inserted into a target
cell membrane. Further conformational changes irreversibly transform the F
protein into a stable six-helix bundle while simultaneously generating a fusion pore
through which the viral genome can be released into the target cell (4).
Work on the fusion proteins of different viruses, including influenza virus
and human immunodeficiency virus, has shown that the TMD plays a significant
role in promoting fusion (29-39). Our lab has explored various aspects of the HeV
F TMD to better understand its role in protein folding, stability, and fusion
promotion. The TMD region has been studied in isolation using sedimentation
equilibrium analysis, an ultracentrifugation method for quantitating protein
molecular masses and protein-protein interactions. Results showed that the HeV
F TMD associated as a trimer in the absence of the rest of the protein (40).
Peptides mimicking the HRB region were added to isolated TMDs and were found
to disrupt TMD-TMD interactions. Though HRB peptides fail to associate in
isolation, they form a trimeric coiled coil within the HeV F prefusion conformation.
The HRB coiled coil acts as a stalk that is N-terminally connected to the globular
head domain and C-terminally connected to the TMDs. Spacing between the HRB
and TMD was shown to be important for protein stability but changes in the spacing
7

did not impact TMD interactions. Together, these results suggest that TMD
interactions contribute to the stability of the HRB region (41).
C-terminal residues of the HeV F TMD were also analyzed to determine
their role in TMD interactions. Mutation of the C-terminal TMD residues
dramatically inhibited fusogenic activity, suggesting that the β-branched residues
in this region promote TMD interactions required for fusion (41). The HeV F TMD
also includes a heptad repeat leucine-isoleucine zipper, and these residues were
shown to be important for HeV F prefusion stability. Overall, these findings
highlight the importance of HeV F TMD interactions for maintaining the metastable
prefusion conformation and for promoting fusion events. These results generated
the hypothesis that the HeV F TMDs must dissociate to initiate refolding events.
This idea is explored in the work described in Chapter 3, in which the HeV F TMDs
were locked together with disulfide bonds to examine the effects on protein stability
and fusion.

Pneumoviruses
Pneumoviridae is another family classified within the Mononegavirales
order. This taxon was previously classified as a subfamily within Paramyxoviridae
but was reclassified in 2016 (42). The pneumovirus genomes, which range from
13 to 15 kilobases, encode 9 to 11 proteins. Pneumovirus virions vary in size and
shape, but they are often filamentous and up to 2 µm in length (42). Two
pneumoviruses that cause disease in humans by infecting epithelial cells of the
respiratory tract are the respiratory syncytial virus (RSV) and human
metapneumovirus (HMPV). This family also includes avian metapneumovirus,
which infects birds, and the murine and bovine orthopneumoviruses, which infect
mice and cattle, respectively.
The pneumovirus life cycle begins with the virus fusing its membrane with
a host cell membrane. Like the paramyxoviruses, this process is mediated by the
F protein which is maintained in a metastable state until it is triggered to undergo
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conformational changes that merge the host cell membrane with the viral lipid
bilayer. In contrast to the paramyxoviruses, studies of RSV and HMPV suggest
that the attachment protein G is dispensable for initiating infection (4). RSV and
HMPV particles are first endocytosed, and fusion events occur within the
endosome (43, 44). For HMPV, low pH has been shown to trigger the F protein for
some strains (45, 46). Since viruses in the Pneumoviridae family possess a
negative-sense RNA genome, the viral particle must also deliver proteins involved
in transcription and replication of the genome, including the large polymerase
protein (L), P protein, M2-1, M2-2, and the N protein, to the host cell. Like the
paramyxovirus N protein, the pneumovirus N protein interacts with the RNA
genome to form the nucleocapsid which protects the genetic material from host
cell nucleases and acts as a template for transcription and replication (47). The P
protein interacts with the N protein and recruits the polymerase and M2-1 to the
viral nucleocapsid to form a replication complex (48). The matrix-2 proteins, M2-1
and M2-2, promote polymerase processivity and regulate the switch between viral
replication and transcription, respectively (49, 50). The polymerase initiates
transcription at the 3’ terminus of the genome and sequentially produces
transcripts for each gene. The genes are separated by non-transcribed intergenic
regions, and each gene contains a short gene start and gene end signal. As the
polymerase moves along, it scans the intergenic regions until it finds the next gene
start sequence. Since the polymerase sometimes falls off during this process,
transcripts for the genes closer to the 3’ terminus are produced in greater
abundance than those at the 5’ terminus. The transcripts are capped and
polyadenylated prior to translation by the host cell ribosome complex (48). Once
the virus accumulates a pool of proteins, it switches from transcription to replication
to produce full-length, positive-sense antigenomes. This switching mechanism is
not fully understood, but it likely involves the M2-2 protein (51). M2-2 is also
thought to play a role in virulence by inhibiting the innate immunity of the host (52).
The polymerase then uses the antigenome as a template to produce negativesense genomes that can be formed into ribonucleoproteins and packaged into new
viral particles. Viral particle assembly is regulated by the matrix protein (M), which
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mediates interactions between the host cell membrane and the ribonucleoprotein
complex (53). Self-assembly of the viral proteins at the plasma membrane is
followed by budding events in which the virus acquires a lipid bilayer.
Human metapneumovirus
HMPV is a member of the Pneumoviridae family that causes acute
respiratory infections. Though HMPV was discovered in the Netherlands in 2001,
research suggests that the virus circulated since at least the 1950s before it was
identified. HMPV was likely not identified earlier due to similarities with the
symptoms of RSV infections and due to difficulties associated with propagating the
virus in cell culture. Respiratory illness linked to HMPV infection can be particularly
dangerous for infants, children, immunocompromised individuals, and the elderly
(49). HMPV consists of two genetic groups known as A and B, which are divided
into the four subgroups A1, A2, B1, and B2 (54). The seasonal pattern for HMPV
infections is similar to other respiratory pathogens, such as RSV and influenza, but
HMPV tends to peak in later months (49). Hospitalization rates for children with
HMPV infections are highest until they reach age one, but reinfections often occur
throughout childhood (49). Nearly all people experience an HMPV infection by the
age of five. However, immunity against the virus is typically weak, so HMPV
infections reoccur in adulthood (55). Symptoms of HMPV infection are similar to
other respiratory viruses and include sore throat, cough, fever, nasal congestion,
and shortness of breath (49). Bronchiolitis and pneumonia are often diagnosed in
conjunction with HMPV infection (49). Currently, there are no approved vaccines
or antivirals to combat HMPV infections.
The HMPV genome is approximately 13,000 nucleotides and includes eight
genes in the following order: 3’-N-P-M-F-M2-SH-G-L-5’. These eight genes
encode nine proteins, since the matrix-2 gene sequence codes for two proteins,
M2-1 and M2-2. With the RNA genome, these proteins form the HMPV particle
which is surrounded by a lipid bilayer derived from the host (FIG 1.4). Unlike RSV,
the HMPV genome does not include the non-structural proteins NS1 and NS2
which are thought to play a role in inhibiting the antiviral response. The F protein,
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G protein, and SH protein are found within the viral membrane. The M protein lines
the inner layer of the viral membrane and plays a role in assembly and budding.
The membrane surrounds the helical nucleocapsid, which interacts with the P
protein, polymerase, M2-1, and M2-2 (52). Delivery of the nucleocapsid into a
target cell leads to the formation of viral factories, called inclusion bodies (IBs), in
the cytoplasm to enhance replication and transcription (FIG 1.5) (56). These
structures are particularly interesting because they represent a potential target for
the development of antivirals to treat HMPV infections.
The role of inclusion bodies in pneumovirus infections
The pneumoviruses HMPV and RSV, along with other specific members of
the Mononegavirales order, form spherical structures known as IBs in the
cytoplasm of infected cells (57-65). Though IBs were once thought to serve as
sites of accumulation for misfolded proteins, they have more recently been shown
to serve as sites of viral replication and transcription for viruses such as HMPV,
RSV, MeV, rabies virus (RABV), and Ebola virus (56, 57, 66-73). These findings
suggest that IB formation is a common mechanism utilized by negative-strand RNA
viruses to promote replication. Viral replication components, including the P
protein, N protein, L protein, and viral RNA, concentrate within IBs to produce viral
transcripts, antigenome, and genome (56, 67). Microscopic analysis of
pneumovirus IB structures has shown that they form in the absence of membranes
and often localize near the nucleus (56, 74). The minimum components required
to reconstitute pneumovirus IB-like structures in cells are the P protein and N
protein (65, 75).
For HMPV, IBs containing viral genomic and antigenomic RNA are easily
detected by 24 hours post infection and were shown to form when smaller
replicative spots coalesce into larger inclusions (56). As the infection progresses
to later time points, IBs are maintained at low numbers within the cell (56). This is
due in part to the fusion of IBs in a cytoskeleton-dependent manner. Though
microtubule polymerization does not appear to be required for IB coalescence,
actin polymerization is critical for forming these structures to promote efficient viral
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replication and transcription (56). The compartments are highly dynamic and
undergo fusion and fission. The dynamics are similar to the nature of cellular
structures such as processing bodies (P-bodies) and stress granules, but HMPV
IBs represent a distinct structure within the cytoplasm to enhance the viral life cycle
(56). Additional studies have shown that HMPV primarily spreads through a direct
cell-to-cell mechanism, in which infected cells form long, branched extensions that
connect to uninfected cells (76). Viral RNA and structures resembling IBs were
identified within extensions, suggesting that the dynamic nature of IBs may be
important for spreading infectious materials to new target cells (76, 77).
RSV inclusions were first described in 1970 using electron microscopy
techniques to study infected cells. The RSV IBs were dense and contained
filamentous structures (64). More recent studies have shown that RSV IBs serve
as a major site for viral RNA synthesis. Similar to HMPV, RSV IBs are not detected
at early time points of infection, suggesting that these structures form as viral
components accumulate in the cytoplasm and as smaller structures coalesce (67).
Additionally, RSV IBs were shown to possess sub-compartments, called IBassociated granules (IBAGs), which concentrate nascent viral mRNA and the M21 protein (67). Interestingly, viral genomic RNA, N protein, P protein, and L protein
were excluded from IBAGs within the IBs (67). These findings suggest that IBAGs
function in sorting viral mRNA with the help of the M2-1 protein, which competes
with the P protein to bind RNA (67). This is the first description of an additional role
for IBs to serve as viral mRNA sorting sites. RSV IBs have also been implicated in
sequestering the NF-κB subunit p65, suggesting that IBs help to antagonize the
innate immune system response from the host (78). Like HMPV, RSV has been
shown to induce the formation of intercellular extensions which may serve as a
route for transporting viral IB components directly from cell-to-cell (79).
Liquid-liquid phase separation and inclusion body formation
The dynamic nature of viral IBs and the similarities they share with other
membrane-less cell structures led to the hypothesis that IBs are liquid organelles
formed via liquid-liquid phase separation (LLPS) within the cytoplasm (FIG 1.6A).
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The biological cell is highly organized to bring specific components together to
increase reaction kinetics. Membranes surrounding classic organelles, such as the
ER and Golgi, provide a physical barrier to concentrate materials for a particular
set of biochemical reactions (80). In addition to membrane-bound compartments,
IBs and other membrane-less compartments concentrate proteins and nucleic
acids in the absence of a physical barrier. Examples include nucleoli, Cajal bodies,
P-bodies, and stress granules which house different varieties of reactions. LLPS,
which is thought to drive the formation of many of these structures, allows for the
concentration of materials to form condensed liquid droplets (81). The nucleolus,
which was first described in the 1830s, was the first membrane-less compartment
to be observed by microscopy (80, 82). Improvements in microscopes led to the
discovery of many other membrane-less compartments within the nucleus, the
cytoplasm, and at the plasma membrane (80). However, scientists have struggled
to explain the properties that allow for the formation and maintenance of these
structures. Analysis of P granules in Caenorhabditis elegans germ cells led to the
first suggestion that these structures were liquid-like in nature (80). Though the
membrane-less compartments found in cells have diverse functions and
characteristics, scientists have now classified them together as biomolecular
condensates since they generally form through the same process of phase
separation (80).
The condensation reaction relies on the formation of weak, multivalent
protein-protein and protein-nucleic acid interactions. This process is influenced by
factors such as pH, protein concentration, charge, RNA-binding, and posttranslational modifications (83). Additionally, protein features such as low
sequence diversity, low-complexity regions, and blocks of oppositely charged
residues often contribute to biomolecular condensate formation (84). Although
LLPS has been implicated in liquid organelle formation for normal cellular
functions, it also plays a role in neurodegenerative disease. In some diseases,
such as amyotrophic lateral sclerosis and Alzheimer’s, mutated proteins in liquid
droplets cause the condensates to undergo a liquid-to-solid transition or to
nucleate aggregation, leading to pathological effects (83). Recent studies of some
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RNA viruses have highlighted LLPS as the mechanism utilized within the
cytoplasm of a host cell to promote processes such as viral replication,
transcription, and assembly. Specifically, several negative-sense, single-stranded
RNA viruses have been shown to form cytoplasmic IBs via LLPS which contain
viral RNA and proteins (64, 83-86) (66, 85-88).
Characterization of proteins that phase separate under physiological
conditions has revealed specific features that are common to these molecules.
Condensates often consist of scaffold proteins, which drive phase separation, and
client proteins, which partition into liquid droplets (83). One protein feature that
promotes multivalent interactions between scaffold proteins, client proteins, and
nucleic acids is intrinsically disordered regions (IDRs), which are dynamic in
solution. IDRs often give proteins the ability to interact with a variety of partners
and are associated with high rates of evolution (89). In addition, proteins with IDRs
are frequently found in condensates that contain RNA (80). HMPV and other
viruses within the Mononegavirales order possess a P protein that acts as a
cofactor for the RNA-dependent RNA polymerase by stabilizing interactions with
the RNA template during replication and transcription. The P proteins of paramyxo, pneumo-, and rhabdoviruses have been shown to include long IDRs (84, 90, 91).
Paramyxovirus and pneumovirus P proteins associate as homotetramers via a
central oligomerization domain that is flanked on both sides by large IDRs. In
contrast, the rhabdovirus P protein contains a central dimerization domain that is
flanked by IDRs (90). The oligomeric and intrinsically disordered nature of these P
proteins allows them to interact with multiple binding partners to form the viral
replication complex.
Negative-sense, single-stranded RNA viruses also possess N proteins with
features that may promote phase separation in cells. First, a cleft of positively
charged amino acids gives the N protein the ability to strongly bind RNA. In addition
to coating the RNA genome to form stable nucleocapsids, a pool of N protein is
maintained in a monomeric state (N0) so that it can be sequestered to the viral
replication complex to bind newly synthesized RNA. Like viral P proteins, some
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viral N proteins contain IDRs. However, the IDRs found in negative-strand virus N
proteins are typically smaller than the IDRs in P proteins. For instance, in the
paramyxovirus MeV, 30 percent of the N protein is disordered, compared to 75
percent of the P protein (91). Together, these viral protein characteristics suggest
that the P protein and N protein are predisposed to participate in LLPS for the
formation of inclusions to enhance viral replication.
HMPV phosphoprotein and nucleoprotein
Since the HMPV P and N proteins represent the minimum requirements for
IB-like structure formation, further analysis of these proteins is needed to
understand how they may regulate LLPS for IB formation during infection. The
HMPV P protein plays various roles during the viral life cycle, particularly during
replication and transcription. It is 294 amino acids in length and contains a stable,
tetrameric coiled coil domain from residue 158 to 237. The hydrophobic amino
acids that line the interior of the coiled coil are highly conserved within the
Pneumoviridae family (84). Overall, the protein sequence includes approximately
35 percent lysine, arginine, glutamic acid, and aspartic acid residues which are
often present in repetitive blocks (84). The tetramerization domain is surrounded
by IDRs at the N- and C-termini (FIG 1.7). Specifically, the N-terminus includes
four long IDRS, and the C-terminus includes four relatively shorter IDRs (47).
HMPV P binds to the polymerase primarily through its central oligomerization
domain and some regions in the C-terminus (92). The disordered regions of the Nand C-termini are available to interact with other proteins to tether them to the
polymerase for replication and transcription activities (92). The disordered HMPV
P N-terminus interacts with RNA-free N (N0). This chaperoning role for the P
protein is common among negative-strand viruses and is crucial so that N does
not oligomerize or bind host nucleic acids (47, 93-96). The interaction is mediated
by a molecular recognition element at the beginning of the N-terminal region of the
P protein (82). This region of P binds to a hydrophobic groove within the C-terminal
domain of HMPV N to block oligomerization (47, 92).
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The C-terminus of HMPV P also plays a role as an adaptor for the N protein
by binding to N-RNA to facilitate interactions with the polymerase (47). This portion
of P is proposed to help remove the template RNA from the ribonucleoprotein
complex to feed it into the polymerase tunnel (47, 92). Interestingly, recent cryoelectron microscopy findings for the HMPV P protein-polymerase complex suggest
that the C-terminal regions of HMPV P occupy non-equivalent positions within the
structure (92). Upon binding to the polymerase, portions of the HMPV P C-terminus
undergo disorder-to-order transitions. This led to the development of a model in
which three HMPV P C-terminal domains displace genomic RNA from the
ribonucleoprotein, while the other P C-terminal domain plays a structural role at
the polymerase tunnel (92). In addition to binding the N0, N-RNA, and the
polymerase, HMPV P is proposed to bind the processivity factor M2-1 via residues
136-161 based on studies of RSV (97-99). Together, these findings highlight the
dynamic nature of the P protein as an adaptor for recruiting viral proteins to the
polymerase.
The HMPV N protein, which consists of 394 amino acids, encapsidates the
viral genome and protects it from host cell nucleases. The protein consists of two
globular domains, the N-terminal domain (NTD) and C-terminal domain (CTD),
which play a role in binding RNA within the positively charged groove located
between the domains. In addition, the domains are attached to NTD and CTD arms
that help the N protomers oligomerize. The N protein is found in two conformations,
depending on whether it is bound to P protein or RNA. HMPV N and other negativestrand virus N proteins are known for their ability to readily bind nucleic acid and
oligomerize into complex structures. Therefore, wild type (WT) HMPV N protein is
generally purified in the form of decameric RNA-bound rings. In the crystallized N
protein ring structure, the RNA is tightly bound between the NTD and CTD within
a positively charged cleft of each N protomer (47). Each N protein interacts with
seven RNA nucleotides. This is unique compared to the closely related
paramyxoviruses which show six nucleotides bound to each N protomer within a
ring structure (47). To form the oligomerized ring, the NTD arm and CTD arm of
each N protein latches to the subsequent N protomer (47). When N0 protein is
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recruited to newly synthesized viral RNA, the P protein is displaced, and the N
protein CTD arm is proposed to flip upward to accommodate the insertion of the
viral RNA into the positively charged cleft (47). Understanding the complex
interactions between HMPV N, P, and viral RNA is crucial for analyzing LLPS
experiments in vitro and in cells.
Methods for analyzing LLPS
Investigations of biomolecular condensates led to the development of
criteria to define the properties of liquid organelles in cells:
1.

Liquid organelles undergo fusion and fission (FIG 1.6B).

2.

The internal contents of liquid organelles diffuse rapidly.

3.

Liquid organelles possess a round shape due to surface tension.
Virologists have used these criteria to study the formation and nature of IBs

in cells. Tools including live cell imaging and fluorescence recovery after
photobleaching (FRAP) have been important for generating qualitative and
quantitative data regarding the dynamics of IBs. For FRAP, fluorescently-tagged
viral proteins have been utilized to assess the diffusion of components within IB
structures (FIG 1.8). FRAP analysis of MeV, RABV, VSV, and RSV IBs has shown
that the contents of these structures possess diffusion rates that are similar to other
known liquid organelles (64, 83, 84, 86) (66, 85, 86, 88). Live cell imaging has
allowed for observation of the spherical shape of viral IBs over time, which is
deformed during fusion and fission events and subsequently recovered.
In addition to cellular studies of IBs, purified protein systems are a powerful
tool for understanding the basic LLPS mechanisms of viral proteins in vitro. The
advantage of conducting experiments with purified proteins is that the simplistic
system allows for the identification of specific components that are required for
phase separation (83). LLPS of purified systems is generally analyzed using light
microscopy, fluorescence microscopy, and turbidity assays. Phase separation of
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the purified protein may be induced by modifying a factor such as ionic strength,
pH, temperature, or by adding RNA or another protein binding partner. The protein
solution can then be plated and imaged with microscope to look for the presence
of liquid droplets.
Turbidity assays are used in conjunction with microscopy analysis to detect
changes in absorbance as protein droplets form in solution. The assemblies scatter
visible light as they form, which can be analyzed using optical density
measurements, generally between wavelengths of 340 and 400 nm (83).
However, turbidity measurements lack some sensitivity because they cannot
differentiate the size or shape of assemblies in solution (83). For instance, a protein
prone to aggregation may give high absorbance readings, even though it does not
form liquid droplets. Thus, turbidity measurements must be considered along with
microscopy results to more clearly determine if a protein phase separates.
Centrifugation is also a useful tool for analyzing proteins that undergo LLPS in
vitro. First, LLPS of a solution is induced by changing specific conditions. Then,
the dense phase that forms is sedimented by centrifugation. The concentration of
the light phase can then be measured spectroscopically (83).
Other in vitro methods provide crucial data for understanding the material
properties of liquid droplets. Though FRAP has been important for analyzing IBs
in cells, it can also be utilized to quantify the mobility of molecules within phase
separated droplets in vitro. This technique has been particularly useful for
understanding the effects of RNA on protein solutions (83). Additionally, fusion of
liquid droplets can be quantitatively analyzed to determine the inverse capillary
viscosity. The inverse capillary viscosity is the ratio of viscosity to surface tension.
With other calculations, this analysis provides data regarding the chemical nature
of the surface of liquid droplets (83). In combination, cellular and in vitro phase
separation experiments provide insight into the mechanisms regulating viral IB
formation for negative-strand viruses. Future efforts to analyze LLPS and viral
replication must focus on bridging the gap between cellular and in vitro work.
Together, these studies will open new doors to understanding how negative-strand
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viruses utilize phase separation dynamics to efficiently replicate and infect new
cells.
Dissertation overview
Cell entry and replication are critical aspects of the basic viral life cycle that
must be understood to effectively combat pathogens which cause human disease.
We are particularly interested in understanding how these processes occur for
negative-strand RNA viruses, which are notable for their high mutation rates. High
mutation rates contribute to viral evolution, which means that these viruses are
excellent at finding new ways to evade the host immune system. Additionally,
these mutations can lead to the emergence of novel infections within humans.
Thus, work on these viruses is important for determining how we can protect
populations against current and future threats. We study the basic mechanisms of
cell entry and replication by analyzing the proteins of HeV and HMPV. Our work
has identified similarities and differences among negative-strand viruses which
may be crucial for learning how we can target these deadly pathogens.
For enveloped viruses, studies of cell entry focus on explaining the
mechanisms that allow for the fusion of two membranes, an energetically
unfavorable process. Years of research on class I fusion proteins have generated
a model for membrane fusion. However, gaps still exist in the model and warrant
further research. The high kinetic barrier associated with membrane merger is
overcome by the fusion protein which sits within the viral membrane. Many copies
of the fusion protein stud the surface of the virus, ready to be triggered to mediate
fusion with a cell. The fusion protein must be held in a metastable prefusion state,
a higher energy conformation, until it is triggered to undergo the irreversible
refolding events which lead to the formation of the lower energy postfusion
conformation. Our interest in viral fusion has focused on the interactions within the
HeV F protein that maintain the stability of the prefusion conformation. In addition,
we have explored changes in these interactions which occur upon triggering. Our
work highlights the importance of the HeV F TMD, which is required for anchoring
the protein and plays a role in proper folding, stability, trafficking, and fusogenic
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activity. Studies of the basic mechanisms of HeV F are needed to build a complete
picture of viral membrane fusion. Novel information that is discovered about
paramyxovirus F proteins may also be beneficial for the development of new
vaccines and therapeutics. In Chapter 3, we explore the hypothesis that HeV F
TMD dissociation is required for subsequent conformational changes that drive
fusion. We tested this idea by locking the TMDs together with disulfide bonds to
see how HeV F stability and fusion would be impacted. Our results provide support
for this hypothesis and show for the first time that blocking HeV F TMD dissociation
abolishes fusogenic activity.
Once cell entry is accomplished, the virus must take on the next challenge
of replicating its genetic material and producing proteins which will be packaged
into new virions. Many negative-strand RNA viruses have evolved mechanisms to
house replication and transcription within distinct cytoplasmic compartments,
which we call IBs. The lack of a physical barrier around these structures creates
challenges for analyzing and targeting the compartments. A combination of cellular
and in vitro studies is important for describing the interactions that allow these
dynamic structures to form. Cellular experiments have provided useful findings
regarding the nature of viral IBs during different stages of infection. Since proteins
and other materials can freely diffuse into IBs in cells, in vitro analysis of purified
viral proteins provides an opportunity to study IB components in isolation. IB
formation is a hallmark of HMPV and RSV infections. Until now, HMPV IBs have
not been characterized as liquid organelles formed by LLPS. In Chapter 4, we
analyze the basic components of HMPV IBs, the N and P proteins, in our in vitro
system to explain the basic interactions that promote IB formation. The HMPV N
and P proteins phase separate to form liquid droplets in vitro, supporting that LLPS
is the mechanism which leads to HMPV IB formation. Additionally, we show that
HMPV P acts as a scaffold protein to recruit oligomeric or monomeric N protein to
liquid droplets, suggesting that the P protein is the driver of LLPS during HMPV
infection.
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Figure 1.1 HeV life cycle. A HeV virion attaches to a target cell via an interaction
between the G protein and the receptor Ephrin B2/B3. The F protein undergoes
conformational changes to merge the viral membrane with the target cell
membrane. The viral genome is released into the cytoplasm where it undergoes
replication and transcription. Replication of the genome yields antigenome which
is then used to generate new negative-sense RNA genome copies. Transcription
of the genome produces viral mRNAs which are translated into viral proteins k and
assembled at the cell surface into new virions. Nascent virions bud from the
surface of the cell to continue the cycle of infection.
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Figure 1.2. Cleavage of HeV F0 to generate F1+F2. The HeV F protein includes
a hydrophobic fusion peptide (FP, pink), heptad repeat A (HRA, yellow), heptad
repeat B (HRB, teal), transmembrane domain (TMD, purple), and C-terminal
cytoplasmic tail (CT, blue). After trafficking to the cell surface, the inactive form of
HeV F (F0) is endocytosed and proteolytically cleaved by cathepsin L into a
disulfide-linked heterodimer (F1+F2). Then, HeV F is transported back to the cell
surface where it can be triggered to promote fusion events.
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Figure 1.3. HeV F processing in the host cell. The precursor F0 (red) is trafficked
through the secretory pathway to reach the plasma membrane. F0 is then
endocytosed and cleaved by cathepsin L within the endosome to generate F1+F2
(blue). The proteolytically activated HeV F is then recycled back to the cell surface.
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Figure 1.4. HMPV particle schematic. The HMPV virion contains a negativesense, single-stranded RNA genome that is coated with N protein. The genome is
enclosed within a lipid bilayer derived from the host cell. The M protein lines the
inside of the viral membrane. The SH, F, and G proteins are transmembrane
proteins within the bilayer. The F protein undergoes conformational changes to
fuse the viral membrane with a target cell membrane. The coated genome can
then be released with its associated proteins into the cytoplasm of the cell where
it can be replicated and transcribed.
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Figure 1.5. HMPV life cycle. An HMPV virion attaches to a target cell, leading to
endocytosis of the particle. The viral particle fuses its membrane with the
endosomal membrane to release the genome and its associated proteins. The
genome is replicated and transcribed in the cell cytoplasm. As the infection
progresses, membrane-less IBs form to house replication and transcription events.
The mRNAs for viral membrane proteins (F, G, SH) are translated at the ER and
trafficked to the cell surface. Viral proteins involved in replication and transcription
are translated in the cytoplasm and then localized to IBs. New viral particles are
assembled at the plasma membrane where they can bud from the surface. The
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virus also induces the formation of cellular extensions for cell-to-cell spread of
infection.
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Figure 1.6. LLPS diagrams. (A) Molecules condense from a single phase to form
a droplet phase. (B) Phase separated liquid droplets are dynamic structures which
can undergo fusion and fission events and then relax into spherical shapes.
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Figure 1.7. HMPV P schematic. HMPV P protomers associate via a central
oligomerization domain to form a tetramer. The oligomerization domain is flanked
by long IDRs that give the protein the ability to interact with a variety of binding
partners.
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Figure 1.8. FRAP diagram. FRAP analysis of live cells requires the use of
fluorescent labels which can be bleached by a laser. After a specific area of
fluorescence is bleached, the fluorescence intensity is monitored over time. This
data can be used to compare fluorescence recovery rates for different structures
within the cell.

29

Chapter 2: Materials and Methods
HeV fusion project
Plasmids
Plasmids containing HeV F and G were kindly provided by Dr. Lin-Fa Wang
from the Australian Animal Health Laboratory. The HeV F TMD mutants were
generated in pGEM using the QuikChange Site-Directed Mutagenesis Kit from
Stratagene and subcloned into pCAGGS using the forward primer 5’ GCG ATT
GAA TTC TAA GCA ATG GCT ACA CAA GAG 3’ and reverse primer 5’ CG GCG
GCC ATG CAT ATT TTA TGT TCC AAT ATA ATA 3’ for PCR amplification. The
constructs were verified by sequencing.
Antibodies
Anti-peptide antibody to the HeV F cytoplasmic tail residues 527-539 (25)
were used to pull down WT HeV F or the TMD mutant constructs. The prefusion
conformation-specific antibody, mAb 5B3, generously provided by Dr. Christopher
Broder (Uniformed Services University of the Health Sciences) was also used to
detect HeV F (100).
Cell lines
Vero cells (ATCC) and BSR cells (provided by Karl-Klaus Conzelman,
Pettenkofer Institut) were maintained in Dulbecco’s modified Eagle’s media
(DMEM; Invitrogen) supplemented with 10% fetal bovine serum (Sigma). For the
BSR cells, 0.5 mg/mL geneticin (Gibco) was added to the media with every third
passage to select for T7 polymerase-expressing cells.
Syncytia assay
Vero cells in 6-well plates were transiently transfected using Lipofectamine
3000 (Invitrogen) per the manufacturer’s protocol with pCAGGS-HeV F and
pCAGGS-HeV G at a 1:3 ratio. At 48 hr post-transfection, the cells were imaged
using a Zeiss Axiovert 100 microscope with a 10X objective.
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Oligomeric analysis
Vero cells in 6-well plates were transiently transfected using Lipofectamine
and Plus (Invitrogen) per the manufacturer’s protocol with pCAGGS-HeV F or one
of the TMD mutants. At 24 hr post-transfection, the cells were washed 2X with PBS
and starved with DMEM lacking cysteine and methionine (Cys-/Met-) for 45 min.
Then, the cells were labeled for 3 hr with Cys-/Met- DMEM containing Tran35Slabel (100 µCi/mL; MP Biomedicals). The cells were washed 3X with PBS and
lysed with 500 µL RIPA lysis buffer (100 mM TrisHCl (pH=7.4), 150 mM NaCl,
0.1% SDS, 1% Triton X-100, 1% deoxycholic acid, 1 mM phenylmethylsulfonyl
fluoride (Sigma), 25 mM iodoacetamide (Sigma), 1:100 aprotinin (Calbiochem)).
The sample lysate was centrifuged at 136,500 x g for 15 min at 4 ºC, and the
supernatant was incubated for 3 hr with 4 µL anti-peptide antibody. Then, the
sample was incubated with 30 µL protein A-sepharose beads (ThermoFisher) for
30 min at 4 ºC with rocking and washed 2X with RIPA buffer + 0.30 M NaCl, 2X
with RIPA buffer + 0.15 M NaCl, and 2X with SDS wash II (150 mM NaCl, 50 mM
Tris-HCl (pH=7.4), 2.5 mM EDTA). Depending on the experiment, the samples
were resuspended with loading buffer lacking or containing dithiothreitol (DTT;
Goldbio) for non-reducing or reducing conditions, respectively. Then, the samples
were boiled and separated using 3.5% polyacrylamide gels for SDS-PAGE and
visualized using the Typhoon imaging system (GE Healthcare). For the tris(2carboxyethyl) (TCEP) (Calbiochem) treatment experiments, 1 mL of 6 mM TCEP
in DMEM supplemented with 10% FBS was added to the cells following the
metabolic label. The cells were incubated with the TCEP solution for 3 hr at 37 ºC
before washing 2X with PBS and adding RIPA lysis buffer. Results were visualized
using the Typhoon imaging system.
Reporter gene assay
Vero cells in 6-well plates were transiently transfected using Lipofectamine
and Plus per the manufacturer’s protocol with 0.8 µg luciferase under the control
of the T7 promoter, 0.9 µg pCAGGS-HeV G, and 0.3 µg pCAGGS-HeV F or one
of the TMD mutants. At 24 hr post-transfection, the Vero cells were washed 1X
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with PBS and overlaid with BSR cells, previously lifted with trypsin (Invitrogen) and
diluted in DMEM supplemented with 10% FBS, that stably express the T7
polymerase for 3 hr at 37 ºC. For specific experiments, 6 mM TCEP was added to
the overlay media for the 3 hr incubation. Then, the cells were lysed with reporter
lysis buffer (Promega) and analyzed for luciferase activity using the luciferase
assay system (Promega) per the manufacturer’s instructions. The Lmax
luminometer (Molecular Devices; Sunnyvale, CA) was used with a 2 sec delay and
a 5 sec integration time. Results were normalized to samples expressing WT HeV
F and G.
Cell surface biotinylation
Vero

cells

in

60-mm

dishes

were

transiently

transfected

using

Lipofectamine and Plus reagent or Lipofectamine 3000 per the manufacturer’s
protocol with 4 µg pCAGGS-HeV F or one of the TMD mutants. At 24 hr posttransfection, the cells were washed 2X with PBS and starved with Cys-/MetDMEM for 45 min. Then, the cells were radiolabeled for 4 hr in Cys-/Met- DMEM
containing Tran35S-label. The cells were washed 2X with ice cold PBS (pH=8.0)
and incubated with 1 mL of 1 mg/mL EZ-Link Sulfo-NHS-Biotin (Pierce) in PBS
(pH=8.0) for 35 min at 4 ºC with rocking followed by 15 min at room temperature.
Next, the cells were washed 3X with ice cold PBS (pH=8.0) and 500 µL RIPA lysis
buffer was added. The sample lysate was centrifuged at 136,500 x g for 15 min at
4 ºC. The supernatant was transferred to 1.5 mL tubes and incubated with 8 µL of
the anti-peptide HeV F antibody for 3 hr at 4 ºC with rocking. Next, each sample
was incubated with 30 µL protein A-sepharose beads for 30 min at 4 ºC with
rocking. The samples were washed 2X with RIPA buffer + 0.30 M NaCl, 2X with
RIPA buffer + 0.15 M NaCl, and 2X with SDS wash II. Following the washes, 60
µL of 10% SDS was added, and the samples were boiled for 10 min, transferred
to a new tube, and repeated with 40 µL of 10% SDS to give a total of 100 µL. Ten
µL of each sample was separated and resuspended in 2X SDS loading buffer
containing DTT for total protein expression analysis. The remaining 90 µL of
sample was treated with 400 µL biotinylation dilution buffer (20 mM Tris (pH=8.0),
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150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.2% bovine serum albumin (US
Biological Life Sciences)) and 30 µL streptavidin beads for 1 hr at 4 ºC with rocking.
The washes described previously were repeated, and the samples were
resuspended in 2X SDS loading buffer containing DTT. After boiling the samples,
analysis of HeV F was conducted using 15% SDS-PAGE and visualized using the
Typhoon imaging system. Quantifications from band densitometry using
ImageQuant 5.2 were reported as relative expression (%), the sum of F0 and F1,
normalized to WT HeV F.
Time course immunoprecipitation
Vero cells in 6-well plates were transiently transfected using Lipofectamine
and Plus per the manufacturer’s protocol with pCAGGS-HeV F or one of the TMD
mutants. At 24 hr post-transfection, the cells were washed 2X with PBS, starved
for 45 min, and metabolically labeled for 3 hr (described previously). Then, the cells
were washed 3X with PBS and chased with DMEM + 10% FBS. At different time
points, the cells were washed 2X with PBS and lysed with RIPA lysis buffer.
Immunoprecipitation was conducted as described for oligomeric analysis, and
samples were resuspended in 2X SDS loading buffer containing DTT. Samples
were boiled and analyzed by 10% SDS-PAGE, and band densitometry
quantifications were performed as described for surface biotinylation.
Immunoprecipitation with prefusion conformation-specific antibody
To analyze mAb 5B3 binding prior to cell disruption, Vero cells in 60-mm
dishes were transiently transfected using Lipofectamine and Plus per the
manufarcturer’s protocol with pCAGGS-HeV F or one of the TMD mutants. At 24
hr post-transfection, the cells were washed 2X with PBS, starved for 45 min, and
metabolically labeled in 2 mL overnight label media (85% Cys-/Met- DMEM, 10%
DMEM + 10% FBS, 5% FBS) containing Tran35S-label for 24 hr. Then, the cells
were washed 3X with PBS and treated with mAb 5B3 at 1 ug/mL in 1X PBS + 1%
bovine serum albumin for 1 hr at 4 ºC with rocking. Following the antibody
incubation, the cells were lysed with RIPA lysis buffer and centrifuged at 136,500
x g for 15 min at 4 ºC. Control samples were treated with 8 µL anti-peptide antibody
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for 1.5 hr after being lysed with RIPA lysis buffer and centrifuged. All samples were
treated with 30 uL protein A-sepharose beads for 1 hr. Then, the samples were
washed as described previously. After boiling the samples, they were separated
by 10% SDS-PAGE, and band densitometry quantifications were performed as
described for surface biotinylation.
To analyze mAb 5B3 binding following cell disruption, Vero cells in 6-well
plates were transiently transfected using Lipofectamine and Plus per the
manufacturer’s protocol with pCAGGS-HeV F or one of the TMD mutants. At 24 hr
post-transfection, the cells were starved, labeled, lysed, and centrifuged as
described for oligomeric analysis. Then, the cells were treated with 1 µg/mL mAb
5B3 or 4 µL anti-peptide Ab for 3 hr. The rest of the immunoprecipitation was
performed as described for oligomeric analysis. Then, the samples were boiled
and separated using 10% SDS-PAGE, and band densitometry quantifications
were performed as described for surface biotinylation.

HMPV phase separation project
Expression and purification of HMPV N0-P
The CAN97-83 HMPV N0-P construct with a 6X C-terminal His6-tag was
purchased from GenScript in the pET-29b(+) plasmid. It was cloned into the
plasmid between the NdeI and KpnI cleavage sites. The construct was expressed
in E. coli Rosetta 2(DE3) competent cells (Novagen) overnight at 18 °C in terrific
broth containing kanamycin after induction at an optical density of 0.8 with 1 mM
isopropyl-β-d-thiogalactopyranoside. Cells were lysed with 20 mM Tris, 500 mM
NaCl, 10 mM imidazole, pH 7 containing cOmplete EDTA-free protease inhibitor
cocktail (Sigma), 125 ug/mL lysozyme, and 250 units of Benzonase (Sigma). After
incubating on ice for 20 min, the solution was sonicated three times at 60%
intensity for 15 sec. The lysate was spun at 18,000 rpm for 45 min at 4 °C. The
crude lysate rocked with HIS-select nickel affinity gel resin (Sigma) for 45 min at 4
°C. The resin was washed one time with lysis buffer and two times with 20 mM
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Tris, 500 mM NaCl, pH 7. The protein was eluted with 20 mM Tris, 500 mM NaCl,
300 mM imidazole, pH 7. The eluate was concentrated and buffer exchanged into
25 mM HEPES, 150 mM KCl, pH 7.5 using a PD-10 desalting column with
Sephadex G-25 resin (GE Healthcare). Alternatively, some N0-P protein
preparations were loaded onto a HiTrap Heparin HP column (Sigma) for further
purification using an increasing NaCl gradient from 200 mM to 1M to remove
nucleic acid from the sample prior to buffer exchange with the PD-10 column. After
buffer exchange, the protein was concentrated, flash frozen, and stored at -80 °C.
Expression and purification of HMPV N-RNA
The CAN97-83 HMPV N construct with a 6X C-terminal His6-tag was
purchased from GenScript in the pET-29b(+) plasmid. It was cloned into the
plasmid between the NdeI and KpnI cleavage sites. The construct was expressed
in E. coli Rosetta 2(DE3) competent cells overnight at 18 °C in terrific broth
containing kanamycin after induction at an optical density of 0.8 with 1 mM
isopropyl-β-d-thiogalactopyranoside. Cells were lysed with 25 mM Tris, 1 M NaCl,
pH 8 containing cOmplete EDTA-free protease inhibitor cocktail, 125 ug/mL
lysozyme, and 250 units of Benzonase. After incubating on ice for 20 min, the
solution was sonicated three times at 60% intensity for 15 sec. The lysate was
spun at 18,000 rpm for 1 hr at 4 °C. The crude lysate was loaded onto a column
containing pre-equilibrated HIS-select nickel affinity gel resin at 4°C. The resin was
washed two times with lysis buffer. The protein was eluted with 25 mM Tris, 1 M
NaCl, 400 mM imidazole, pH 8. The eluate was concentrated and the NaCl
concentration of the sample was adjusted to 100 mM using 25 mM Tris, pH 8.
Then, the sample was loaded onto a HiTrap Heparin HP column using an
increasing NaCl gradient from 200 mM to 1M. Fractions containing the HMPV N
protein were concentrated and buffer exchanged into 25 mM HEPES, 150 mM KCl,
pH 7.5 using a PD-10 desalting column with Sephadex G-25 resin. The protein
was then concentrated, flash frozen, and stored at -80 °C.
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Expression and purification of HMPV P
The CAN97-83 HMPV P construct was cloned into the plasmid pET 302/NTHis between the cleavage sites EcoRI and XhoI. The construct was expressed in
BL21(DE3) CodonPlus RIL cells (Agilent) overnight at 37 °C in terrific broth
containing ampicillin after induction at an optical density of 1.4 with 1 mM isopropylβ-d-thiogalactopyranoside. Cells were lysed with 20 mM Tris, 200 mM NaCl, pH
7.5 containing cOmplete EDTA-free protease inhibitor cocktail and 125 ug/mL
lysozyme. After incubating on ice for 20 min, the solution was sonicated three times
at 60% intensity for 15 sec. The lysate was spun at 18,000 rpm for 30 min at 4 °C.
The crude lysate rocked with HIS-select nickel affinity gel resin (Sigma) for 45 min
at 4 °C. The resin was washed one time with lysis buffer and two times with 20 mM
Tris, 200 mM NaCl, 20 mM imidazole, pH 7.5. The protein was eluted with 20 mM
Tris, 200 mM NaCl, 250 mM imidazole, pH 7.5. The eluate was loaded onto a
HiTrap Q HP anion exchange chromatography column (Cytiva). The column was
washed with 20 mM Tris, pH 7.5. Then, fractions were eluted with 20 mM Tris, 1
M NaCl, pH 7.5. The fractions containing HMPV P were concentrated and buffer
exchanged into 25 mM HEPES, 150 mM KCl, pH 7.5 using a PD-10 desalting
column with Sephadex G-25 resin.
To reduce nucleic acid binding, some HMPV P lysates were treated with
Benzonase during the cell lysis step. Instead of anion exchange, the HIS-select
purification was followed by heparin purification using a HiTrap Heparin HP column
with an increasing NaCl gradient from 200 mM to 1M prior to buffer exchange with
the PD-10 column. After buffer exchange, the protein was concentrated, flash
frozen, and stored at -80°C.
Protein labeling
Prior to buffer exchange, immobilized metal affinity chromatography (IMAC)
purified HMPV N0-P was labeled with Alexa 488 TFP ester (ThermoFisher). The
Alexa 488 TFP ester was prepared with DMSO to make a 10 mg/mL solution. The
solution was added dropwise to the HMPV N0-P protein sample. The sample
rocked for 1 hr in the dark. A PD-10 column was used to buffer exchange the
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sample into 25 mM HEPES, 150 mM KCl, pH 7.5. After buffer exchange, the
protein was concentrated, flash frozen, and stored at -80°C. Anion exchange
purified HMPV P was labeled in a similar manner using Alexa 594 NHS ester
(ThermoFisher).
Droplet assay
A 20% dextran solution was prepared in 25 mM HEPES, 150 mM KCl, pH
7.5. The solution was filter sterilized prior to use. DTT was added to the dextran
solution to give a final concentration of 1 mM. HMPV protein constructs were
diluted in the 20% dextran, 1 mM DTT, 25 mM HEPES, 150 mM KCl, pH 7.5
solution in 1.5 mL Eppendorf tubes. This solution was used in samples for standard
droplet imaging, fusion droplet imaging, and in turbidity assays. For the HMPV P
samples tested at different KCl concentrations, similar buffers were prepared with
KCl ranging from 0 mM to 500 mM. 1.5 µL of sample was plated on an 8-well
printed microscopy slide and covered with a glass coverslip. For droplets imaged
at later time points, the slides were stored in a humidified chamber
Microscopy imaging
HMPV samples were imaged using either DIC or epifluorescence on a
Nikon Eclipse E600 with the 60X objective. Fusion time lapse images were
acquired with MetaMorph software using DIC on a Zeiss Axiovert 200M with the
100X oil objective. Images were acquired at 0.3 sec or 0.5 sec intervals.
RNA
The fluorescent RNA decamer was purchased from Integrated DNA
Technologies. It was terminated with OH at the 5’ end and 6-carboxyfluorescein at
the 3’ end.
Turbidity assay
Protein solutions were mixed with filter sterilized 20% dextran, 1 mM DTT,
25 mM HEPES, 150 mM KCl, pH 7.5 in clear 96-well plates. The final concentration
of the proteins was 40 µM. The absorbance of the solutions was measured on a
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SpectraMax iD3 at 395 nm (87). Readings were taken at 5 min intervals for 8 hr or
longer.
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Chapter 3: Transmembrane Domain Dissociation is Required for Hendra F
Protein Fusogenic Activity
Portions of this chapter were adapted and reprinted with permission from
the American Society for Microbiology: Slaughter KB, Dutch RE. 2019.
Transmembrane Domain Dissociation Is Required for Hendra Virus F Protein
Fusogenic Activity. J Virol 93:e01069-19.

Introduction
The Paramyxoviridae family consists of negative-sense single-stranded
RNA viruses enclosed within lipid membranes. Hendra (HeV) and Nipah (NiV)
viruses, members of the Henipavirus genus, are highly pathogenic zoonotic
viruses within the Paramyxoviridae family (101). Due to the high mortality rates
associated with HeV and NiV infections and the lack of a human vaccine or
effective treatment, they have been designated as biosafety level 4 pathogens
(102). HeV and NiV were identified in Australia and Malaysia, respectively, in the
1990s following outbreaks of severe encephalitis and respiratory disease in
humans (8, 102-104). Further investigation revealed that fruit bats of the
Pteropodidae family were the natural reservoir for the viruses, and transmission to
other organisms, including pigs and horses, contributed to the zoonotic spread to
humans (105-107). The potential for future outbreaks of henipavirus infections and
the emergence of similar zoonotic viruses warrants further research into the entry
mechanisms of these pathogens.
Membrane fusion is an essential step in entry of enveloped viruses that
relies on the coordination of specialized proteins at the viral membrane surface.
HeV and NiV possess two surface glycoproteins: the attachment protein (G), which
allows the virus to bind a target cell, and the fusion protein (F), which promotes
merger of the viral membrane with the target membrane (108, 109). Both
glycoproteins, F and G, are required for paramyxovirus membrane fusion, but it is
still unclear how interactions between F and G and receptor binding promote
triggering of F (18). The henipaviruses and other members of the Paramyxoviridae
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family use a trimeric class I F protein to drive membrane fusion (20, 110, 111).
Before the F protein can participate in fusion events, the inactive precursor (F0)
must be proteolytically cleaved within the host cell to form a fusion active disulfidelinked heterodimer (F1+F2) (FIG 3.1A). For HeV and NiV, the F protein traffics to
the cell surface and is subsequently endocytosed to be cleaved by the protease
cathepsin L before being recycled back to the surface (24-26). Following the
cleavage event, the F protein is maintained at the surface in a metastable prefusion
state until it is triggered to undergo the conformational changes needed to promote
membrane fusion. These conformational changes from the prefusion to post-fusion
form involve an essentially irreversible rearrangement of the F protein ectodomain
that results in formation of a stable six-helix bundle (FIG 3.1B-F).
Studies of several viral fusion proteins have shown that the transmembrane
domain (TMD) is critical for driving fusion events (29, 30, 33-39, 112, 113). For
HeV, previous work has shown that TMD interactions within the F protein trimer
help preserve the metastable prefusion conformation and play a role in fusion
promotion (41, 114, 115). More specifically, these findings suggest that HeV F
TMD interactions are needed to stabilize the heptad repeat B (HRB) domains that
form the stalk of the protein prior to triggering (FIG 3.1B). Thus, the current model
for HeV F fusion events suggests that dissociation of TMD trimeric interactions is
required to initiate conformational changes that destabilize interactions between
the HRB domains and eventually promote formation of the post-fusion six-helix
bundle to drive membrane fusion (41).
Based on this model, we hypothesized that fusion could be blocked by
introducing disulfide bonds to covalently link the TMDs of HeV F. Studies using
substituted cysteine residues to generate disulfide bonds have previously been
conducted to examine conformational changes in paramyxovirus surface
glycoproteins. For measles virus (MeV), residues in the attachment protein stalk
were replaced with cysteine to promote disulfide bond formation to identify four
conserved residues required for folding into a fusion-conducive conformation
(116). In addition, studies of the attachment proteins from canine distemper virus
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and MeV showed that introduced disulfide bonds in the central region of the stalk
blocked fusion, but fusion activity was restored under reducing conditions (117).
For the Newcastle disease virus attachment protein, disulfide bonds were
generated across the dimer interface in the globular domain to show changes in
receptor binding and fusion promotion (118).
Introduced disulfide bonds have also been an important tool for studying
paramyxovirus F proteins. Single cysteine substitutions were made in the
membrane-proximal region of the heptad repeat B (HRB) domain of MeV F,
generating disulfide-linked dimers, to study formation of the post-fusion six-helix
bundle. Results showed that the constructs were able to promote efficient viral
entry even though two HRB domains were locked together by a disulfide bond
(119). Other studies have used double cysteine substitutions to further restrict
conformational changes in the paramyxovirus F protein. For MeV F, introduced
disulfide bonds that linked the globular head and stalk domain of different
monomers within the F trimer blocked fusion activity, and fusion was partially
restored by subsequently reducing the disulfide bridges. These findings suggested
that fusion activity requires reversible interactions between the stalk and head
domains of the F protein (120). For PIV5 F, double cysteine substitutions were
used to introduce disulfide bonds in the membrane-proximal external region
(MPER) which is N-terminal to the TMD. Results from this study showed that
dissociation of the MPER region within the PIV5 F trimer is necessary to promote
the conformational changes that drive fusion events (121). Additionally, work on
HeV F used double cysteine substitutions to block conformational changes in the
ectodomain to analyze effects on fusion. This study showed that introduced
disulfide bonds in the ectodomain could inhibit fusion by stabilizing HeV F in the
prefusion conformation (122).
Previous evidence and calculations for paramyxoviruses have shown that
the TMDs of the F protein are potentially longer than a typical vertically inserted
membrane-spanning helix (112). Due to the lack of structural data for membranespanning regions, the orientation of the paramyxovirus F protein TMDs within the
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membrane remains unclear. We selected residues near the N-terminal region of
the predicted HeV F TMD for substitution with double cysteine residues to
determine if TMD dissociation is essential to drive conformational changes
required for fusion events (FIG 3.1A). These TMD mutants were designed with the
goal of introducing disulfide bonds that would link the three monomers of the F
trimer in the TMD region to assess alterations in fusion activity, protein stability,
and overall protein conformation.
Double cysteine substitutions in the HeV F TMD led to the formation of
disulfide-linked trimers, and fusion was blocked for these mutants. Attempts to
restore fusion for the mutants with a disulfide reducing agent were unsuccessful,
suggesting that the introduced disulfide bonds were protected in the membrane.
Further analysis showed that two of the mutants were expressed at the cell surface
in the prefusion conformation at levels that would normally promote fusion. Our
results suggest that these two mutants were properly folded and processed,
supporting the conclusion that TMD dissociation is required for fusion promotion.
This study is the first to show that HeV F fusogenic activity can be prohibited by
blocking TMD dissociation. These findings provide important new information on
paramyxovirus fusion and contribute to our current knowledge of HeV F TMD
interactions in protein stability, conformation, and fusion promotion events.

Results
Double cysteine substitutions in the HeV F TMD promote disulfide bond
formation
Our current model suggests that TMD dissociation is important for
conformational changes in the ectodomain needed for fusion, so substitutions were
made in the HeV F TMD to analyze the effects on protein folding, stability, and
fusion promotion when the TMDs are locked together. HeV F associates as a
homotrimer immediately following synthesis, so double cysteine substitutions were
made to link the three monomers with disulfide bonds (T483C/V484C,
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V484C/N485C, N485C/P486C). The mutation locations were selected based on
the prediction that the residues were present in the N-terminal region of the HeV F
TMD. HeV F is synthesized in the endoplasmic reticulum (ER) which has a thinner
lipid bilayer than the plasma membrane (123). Our goal was to mutate residues in
the TMD that could be exposed to the oxidizing environment of the ER to allow for
disulfide bond formation before trafficking to the cell surface.
The oligomeric state of the HeV F TMD mutants was analyzed to determine
if disulfide bonds successfully linked the monomers of the HeV F trimer. Vero cells
were transiently transfected with plasmids encoding WT HeV F or one of the TMD
mutants. Then, cells were starved, metabolically labeled, and samples
immunoprecipitated using an anti-peptide antibody that binds to the cytoplasmic
tail of HeV F. Boiled samples were separated on 3.5% polyacrylamide gels under
non-reducing conditions to allow for visualization of different oligomeric forms of
HeV F. T483C/V484C, V484C/N85C, and N485C/P486C migrated primarily in the
trimeric form, whereas WT HeV F migrated primarily as a monomer (FIG 3.2A).
This suggested that the double cysteine substitutions in HeV F resulted in disulfide
bonds that covalently linked the monomers of the HeV F trimer. In contrast, WT
HeV F migrated primarily in the monomeric form because the monomers of the
trimer lack covalent interactions. To confirm that the trimeric form was a result of
introduced disulfide bonds, samples were alternatively treated under reducing
conditions. Results showed that the HeV F TMD mutants migrated in the
monomeric form, similar to WT HeV F, under reducing conditions (FIG 3.2B).
Taken together, these findings indicate that the monomers of T483C/V484C,
V484C/N85C, and N485C/P486C were effectively cross-linked due to the
introduction of disulfide bonds between the TMDs of the F trimer.
Fusogenic activity is blocked for the HeV F TMD mutants
Fusion assays were conducted to determine whether the mutants could
promote fusion when TMD dissociation was inhibited. Vero cells were transiently
transfected with plasmids encoding WT HeV G and WT HeV F or one of the TMD
mutants. Cells transfected with WT HeV G alone or empty vector served as
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negative controls. At 48 hr post-transfection, the cells were analyzed by
microscopy for syncytia formation. As expected, cells transfected with a
combination of WT HeV F and G showed the formation of small and large syncytia
(FIG 3.3A). However, samples transfected with WT HeV G and one of the TMD
mutants showed no syncytia formation, suggesting that the introduced disulfide
bonds blocked normal fusion promotion (FIG 3.3A).
A quantitative luciferase reporter gene assay was used to confirm the
syncytia assay results. Vero cells were transiently transfected with plasmids
encoding luciferase under the control of a T7 promoter, WT HeV G, and WT HeV
F or one of the TMD mutants. At 24 hr post-transfection, the Vero cells were
overlaid with BSR cells containing the T7 polymerase. After a 3 hr incubation, the
cells were lysed and analyzed for luminescence as a measure of cell-cell fusion.
Results showed that the TMD mutants did not promote fusion above the levels
observed for the negative control (HeV G alone). Together, these results indicate
that introduced disulfide bonds in the HeV F TMD prohibit fusion activity.
Cell surface expression is variably reduced for the HeV F TMD mutants
Previous studies have shown that increased cell surface density of WT HeV
F correlates with increased fusion activity (124). Cell surface expression analysis
was performed to determine if the TMD mutants were trafficked to the surface at
levels that would normally allow for fusion promotion. Vero cells were transiently
transfected with WT HeV F or one of the TMD mutants, starved, and metabolically
labeled. Then, the samples were biotinylated prior to lysis and immunoprecipitation
so that the cell surface protein population could be isolated and compared to total
protein levels via SDS-PAGE analysis. Results for total protein expression showed
no significant differences for the TMD mutants compared to WT HeV F (FIG 3.4A,
3.4C), whereas protein cleavage was significantly reduced for the mutants (FIG
3.4D), indicating they may be processed and trafficked less efficiently. Analysis of
cell surface protein expression and cleavage showed significantly reduced levels
for N485C/P486C, suggesting that this mutant may be misfolded or have severe
trafficking defects (FIG 3.4B, 3.4E). Similar to total protein cleavage results,
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surface protein cleavage levels for the TMD mutants were significantly reduced,
further indicating that they are trafficked and processed less efficiently than WT
HeV F (FIG 4F). Although T483C/V484C and V484C/N485C cleavage was
reduced, the amount of fusion active F1 on the surface was above the level
previously shown to be needed for HeV F fusion (124). Based on these results,
T483C/V484C and V484C/N485C are likely unable to promote fusion because
TMD dissociation is an essential step for initiating conformational changes during
fusion events.
T483C/V484C and V484C/N485C are maintained over time at levels that
normally allow for fusion
Since the HeV F TMD mutants showed moderate differences in total
expression and variable differences in surface expression compared to WT HeV
F, a time course immunoprecipitation experiment was performed to monitor
stability of the F protein over time (FIG 3.5). Vero cells were transiently transfected
with WT HeV F or one of the TMD mutants. Then, the cells were starved,
metabolically labeled, and chased with regular media for different amounts of time,
as indicated. Finally, cells were lysed and samples immunoprecipitated for SDSPAGE analysis. At early time points, WT HeV F and the TMD mutants were
predominantly found in the F0 inactive form (FIG 3.5A). Over time, levels of the F1
proteolytically active form increased, indicating that WT HeV F and the mutants
were processed. Interestingly, quantification of expression levels at different time
points showed that the mutants were highly expressed compared to WT HeV F at
early time points (FIG 3.5B). At later times, T483C/V484C and V484C/N485C
showed reductions in protein levels compared to WT HeV F, indicating that these
mutants may have minor folding changes that target some of the protein for
degradation. However, N485C/P486C showed a more severe reduction in protein
level over time, suggesting that this mutant is likely targeted for degradation after
synthesis due to improper folding. This result is consistent with the finding that
N485C/P486C surface expression was significantly reduced (FIG 3.4). Overall,
these results show that the location of introduced disulfide bonds in the HeV F
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TMD can variably affect protein folding and stability over time. These findings
suggest the minor changes observed for T483C/V484C and V484C/N485C protein
stability are likely not the cause of fusion prohibition.
Introduced disulfide bonds in the HeV F TMD mutants are poorly accessible
to reducing agent
Since fusion assays with the TMD mutants suggested that TMD dissociation
is essential for fusion promotion, the mutants were analyzed to determine if fusion
could be restored by reducing the introduced disulfide bonds. In theory, reduction
of the disulfide bonds linking the TMDs would allow for dissociation of the TMDs
to initiate the necessary conformational changes in the ectodomain for fusion
activity. To test this, a luciferase reporter gene assay was conducted as described
previously, except that the overlay media contained the cell-impermeant reducing
agent tris(2-carboxyethyl)phosphine (TCEP). Following the 3 hr incubation with
overlaid BSR cells in 6 mM TCEP-containing media, the samples were analyzed
for luminescence. Interestingly, fusion increased for WT HeV F treated with TCEP,
suggesting that reduction of intramolecular disulfide bonds may impact overall
protein stability and enhance triggering (FIG 3.6A). However, results for the TMD
mutants showed no significant change in fusion levels between treated and
untreated samples, indicating that fusion was not restored in the presence of TCEP
(FIG 3.6A).
Oligomeric analysis was performed to further understand the effects of
TCEP on the introduced disulfide bonds in the TMD mutants. The samples were
prepared as described in FIG 3.2, except a 3 hr incubation with 6 mM TCEP or
untreated media was included after the metabolic label. Then, samples were
immunoprecipitated and analyzed by SDS-PAGE. Interestingly, results of the
analysis showed that TCEP was capable of reducing disulfide bonds within the WT
F protein, as indicated by the shift in bands for the trimer, dimer, and monomer in
treated samples (FIG 3.6B). This shift is consistent with loss of the extracellular F2
subunit when F1+F2 is reduced in the presence of TCEP. The TMD mutants also
showed shifts consistent with loss of the F2 subunit (FIG 3.6B, asterisks).
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T483C/V484C showed some reduction from the trimeric to monomeric form, but a
portion of the trimeric form was still present in the TCEP-treated samples. The
trimeric form of V484C/N485C partially shifted to a trimer lacking F2 in the TCEPtreated samples, but there was little change in the amount of monomer. The
oligomeric forms of N485C/P486C remained relatively unchanged following TCEP
treatment. This indicates that TCEP was poorly able to access the introduced
disulfide bonds linking the TMDs of the mutant HeV F proteins, and accessibility
decreased as the mutations went further into the TMD region. Altogether, this data
suggests that the introduced disulfide bonds in the mutants are likely buried in cell
membrane, making them, in some cases, inaccessible to the reducing agent.
T483C/V484C and V484C/N485C bind a prefusion conformation-specific
antibody prior to cell disruption
Since T483C/V484C and V484C/N485C were present at the cell surface at
levels that would allow for fusion, further studies were conducted to analyze the
conformation of the mutant protein structures. A HeV F prefusion conformationspecific antibody, mAb 5B3, was used to compare WT HeV F to the TMD mutants
(100, 122). Vero cells were transiently transfected with WT HeV F or one of the
mutants. At 24 hr post-transfection, the cells were metabolically labeled overnight
and treated with the prefusion antibody prior to cell lysis and immunoprecipitation.
Control samples were treated with the HeV F anti-peptide antibody after cell lysis.
Results showed that T483C/V484C and V484C/N485C were able to bind the
prefusion conformation-specific antibody at moderately reduced levels compared
to WT HeV F (FIG 3.7A, 3.7B). This result is consistent with the cell surface protein
expression levels observed for T483C/V484C and V484C/N485C, suggesting that
the TMD mutants trafficked to the surface are present in the prefusion form (FIG
3.4).
Prior work with the prefusion conformation-specific antibody has shown that
WT HeV F is unable to bind the antibody when it is applied following cell lysis, likely
due to disruption of the metastable prefusion conoformation of HeV F following
lysis buffer treatment. Since the TMDs of T483C/V484C and V484C/N485C are
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locked together by disulfide bonds, these mutants were tested to determine if the
introduced disulfide bonds permanently lock the prefusion conformation of the
ectodomain. The HeV F TMD mutants were tested with mAb 5B3 after cell lysis to
analyze prefusion conformation-specific antibody binding, and results showed that
treating the mutants with mAb 5B3 following cell disruption dramatically reduced
levels of binding (FIG 3.7C). Together, these results suggest that T483C/V484C
and V484C/N485C are synthesized in a prefusion conformation, but locking the
TMDs together with disulfide bonds does not completely prevent unfolding of the
ectodomain.

Discussion
The model for HeV fusion suggests that dissociation of the F protein TMDs
is an essential step for initiating and completing conformational changes in the
ectodomain required for membrane fusion (41). We tested this model by designing
HeV F TMD mutants to introduce disulfide bonds that would link the TMDs and
prevent trimeric dissociation. Results showed that the mutants were successfully
synthesized as disulfide-linked trimers, but fusion was prohibited for the mutants,
suggesting that TMD dissociation is critical for the conformational changes in HeV
F needed for fusion. Whereas surface expression and stability of T483C/V484C
and V484C/N485C were maintained at levels that would allow for fusion, our
results showed that N485C/P486C surface expression was significantly reduced,
suggesting that the position of these introduced disulfide bonds interfered with
proper protein folding. Attempts to restore fusion for the TMD mutants were
unsuccessful, indicating that the introduced disulfide bonds were poorly accessible
to the reducing agent due to their position in the membrane. Additional analysis of
the TMD mutants showed that T483C/V484C and V484C/N485C were maintained
in a prefusion conformation prior to cell disruption. Together, these findings support
the hypothesis that TMD dissociation is required for HeV fusogenic activity and
that TMD interactions play a crucial role in F protein folding and stability.
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Cleavage of the HeV F TMD mutants was significantly reduced compared
to WT HeV F, which could contribute to the lack of fusion. Previous work from our
lab showed that decreased WT HeV F expression leads to decreased fusion
activity, but fusion was still detectable when normal WT HeV F surface expression
was reduced by 80 percent (124). The amount of active F1 protein at the surface
for the mutants T483C/V484C and V484C/N485C was above that needed for
fusion for the WT protein. However, our reporter gene assay results showed no
fusion above background levels for the HeV F TMD mutants, supporting our
conclusion that fusion is blocked.
Previous work with other paramyxoviruses has utilized introduced disulfide
bonds to probe the effects of limiting mobility within the F protein. For PIV5,
introduced disulfide bonds that linked the monomers within the MPER, N-terminal
to the predicted TMD, blocked fusion activity (121). This was consistent with the
inhibition of fusion observed for the HeV F TMD mutants. Treatment of the PIV5 F
MPER mutant with TCEP restored fusion activity. However, similar treatment of
the HeV F TMD mutants with TCEP did not restore fusion. This suggests that the
disulfide bonds of the HeV F TMD mutants in this story were protected in the
membrane, whereas the MPER disulfide bonds in the PIV5 F mutant were exposed
at the cell surface (121).
Additional work related to PIV5 F has addressed the role of the TMD in
fusion. Investigations showed that single cysteine substitutions near the Nterminus of the TMD led to disulfide bond formation in the absence of an oxidative
cross-linker, similar to the disulfide bond formation we observed in the HeV F TMD
mutants (112). Further analysis of this region of PIV5 F using alanine-scanning
mutagenesis indicated that two residues, L486 and I488, were required for efficient
fusion activity. Different amino acids were substituted at these sites to test the
effects of amino acid side chains on fusion activity. Interestingly, substitution with
cysteine led to a minor reduction in fusion activity compared to the severe
reductions observed with other substitutions. This finding is consistent with the
idea that disulfide bond formation, rather than the presence of substituted cysteine
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residues, drove the prohibition of fusion activity for the HeV F TMD mutants. In
addition, an alanine substitution was previously made at residue 486 in HeV F,
resulting in minimal changes in fusion activity compared to WT, further suggesting
that disulfide bond formation, rather than the cysteine substitutions, played a key
role in blocking fusion activity for the HeV F TMD mutants (Barrett, Popa,
unpublished data).
Single cysteine substitutions were also used in a study to examine
conformational changes in MeV F. They generated disulfide-linked mutants that
were predicted to be unable to fully close the six-helix bundle (119). The single
substitutions were made near the membrane-spanning region in the HRB domain.
Despite this restriction on F protein flexibility, the mutants were able to efficiently
open and stabilize fusion pores for viral entry, suggesting that these fusion events
occur independently of complete six-helix bundle assembly (119). This work
indicates that these single cysteine substitutions allow for greater flexibility than
double cysteine substitutions in the membrane-proximal region of the F protein and
provide evidence to support the idea that flexibility of interactions in the HRB and
TMD are required for efficient fusion activity.
When TCEP was used in an attempt to restore fusion activity in our study,
results showed that fusion was enhanced for WT HeV F. This increase may be
due to the reduction of other disulfide bonds within the ectodomain of HeV F that
are required for prefusion stability. Work on Newcastle disease virus identified free
thiols in the surface-expressed F protein, a result of thiol/disulfide-exchange, and
blocking these groups with a thiol-specific biotin inhibited fusion (125).
Thiol/disulfide-exchange also plays a role in the entry of other enveloped viruses
such as human immunodeficiency virus type I (126). These findings suggest that
reduction of specific disulfide bonds in the F protein of paramyxoviruses may affect
the efficiency of fusion activity. For HeV F, reducing disulfide bonds in the
ectodomain by adding TCEP may cause the protein to trigger and promote fusion
more readily than untreated HeV F. The HeV F TMD mutants showed small
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increases in fusion following TCEP treatment. However, these changes in fusion
activity were not significant when compared to the untreated mutants.
The paired cysteine substitutions we made in HeV F were located near the
N-terminus of the TMD, but our results suggested that the introduced disulfide
bonds were buried within the plasma membrane. The F protein is synthesized in
the ER which consists of a slightly thinner lipid bilayer than the plasma membrane
(123). This difference in membrane thickness may be important for exposing the
N-terminal region of the HeV F TMD to the oxidizing environment of the ER to allow
for disulfide bond formation immediately following synthesis. Once the mutant HeV
F proteins are trafficked through the secretory pathway to the thicker plasma
membrane, the disulfide bonds in the TMD may be shielded by the lipid
environment from extracellular factors that could be introduced to disrupt the
bonds.
Membrane thickness is largely determined by lipid composition, and a
number of membrane lipids have been identified as important players in viral
infectivity (127-133). Additionally, several studies of non-viral proteins have shown
that cholesterol and sphingolipids play a role in promoting TMD helix interactions
(134-136). Work with the paramyxovirus MeV has shown that the F protein is
enriched in lipid rafts, and this partitioning is important for MeV assembly at the
plasma membrane (132). Studies of NiV have shown evidence of F protein
clustering in the plasma membrane, suggesting that membrane domains may be
needed for proper surface glycoprotein organization for assembly and fusion (137).
For Newcastle disease virus, lipid rafts have been shown to participate in forming
and maintaining F protein and attachment protein complexes in the plasma
membrane (138). Beyond paramyxoviruses, lipid rafts domains have been
implicated in the assembly and spread of filoviruses, retroviruses, and
orthomyxoviruses (139). It is possible that lipid rafts also play a role in HeV
assembly and TMD helix interactions. Additionally, partitioning of the F protein into
rafts could increase the number of TMD residues accommodated by the
membrane. Therefore, HeV F localization to lipid rafts could explain why the
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introduced disulfide bonds are initially formed at the ER but are protected from
reducing agents at the plasma membrane. Future studies will analyze the
importance of lipid composition for stability of the prefusion conformation and
promotion of fusion events.
Here, we showed that disulfide bonds can be introduced to covalently link
the TMDs of the HeV F trimer. Blocking TMD dissociation with introduced disulfide
bonds prohibits fusion events, but further studies are needed to address the
conformational changes that can occur in HeV F when the TMDs are locked. Our
studies suggest that mutant HeV F proteins with linked TMDs are in some cases
capable of maintaining a prefusion conformation. If cells expressing these
constructs are disrupted, then the mutant HeV F proteins refold into a conformation
that is no longer recognizable by a prefusion specific antibody. Additional analysis
is needed to understand if the disulfide-linked HeV F mutants are capable of
refolding into protein intermediates that are suggested to occur after an initial
triggering event and prior to formation of the six-helix bundle. Our findings reported
here and future studies will contribute to understanding HeV F dynamics required
for fusion events and mechanisms of enveloped virus entry.
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Figure 3.1. HeV F protein schematic and fusion model. (A) Diagram of the
fusion-active, disulfide (S-S)-linked F protein with the HeV F TMD sequence below.
Domain structure includes the fusion peptide (FP), heptad repeat A (HRA), HRB,
TMD, and the cytoplasmic tail (CT). In the fusion model, the TMDs of the
metastable prefusion F interact as a trimer (B). Then triggering of F leads to
dissociation of the TMDs and the HRB domains (C). Changes in TMD interactions
promote extension of the HRA domains and insertion of the FP into the target
membrane (D). (E and F) Further refolding of F leads to formation of the postfusion
six-helix bundle conformation.
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Figure 3.2. Double cysteine substitutions in the HeV F TMD promote disulfide
bond formation. Vero cells were transfected with WT HeV F or one of the TMD
mutants. At 24 h posttransfection, the cells were metabolically labeled for 3 h, and
samples were immunoprecipitated. WT HeV F and the mutants were treated with
nonreducing loading buffer (A) or reducing loading buffer (B) and separated using
3.5% SDS-PAGE.
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Figure 3.3. Fusogenic activity is blocked for the HeV F TMD mutants. (A) Vero
cells were transfected with the attachment protein WT HeV G and WT HeV F or
one of the TMD mutants. Syncytium formation was analyzed at 48 h
posttransfection. Images were taken with a Zeiss Axiovert 100 microscope. White
arrowheads indicate syncytia. Images are representative. (B) Vero cells were
transfected with luciferase, WT HeV G, and WT HeV F DNA or one of the TMD
mutants. At 24 h posttransfection, the Vero cells were overlaid with BSR cells. After
a 3-h incubation period, the cells were lysed and prepared for luminosity analysis
to quantify fusion. Results were normalized to samples transfected with WT HeV
F and G. All data are presented as the means ± standard deviations for three
independent experiments. Statistical analysis was performed using a two-way
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analysis of variance with a Bonferroni correction. Asterisks indicate statistical
significance compared to values for the WT HeV F (****, P < 0.0001).
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Figure 3.4. Cell surface expression is variably reduced for the HeV F TMD
mutants. Total (A) and surface (B) expression levels were analyzed using a
biotinylation method. Vero cells were transfected with WT HeV F or one of the TMD
mutants. At 24 h posttransfection, the cells were metabolically labeled for 4 h,
followed by biotinylation of the surface proteins and immunoprecipitation. The
samples were analyzed by 15% SDS-PAGE. Total expression (F0+ F1) and
cleavage [F1/(F0+F1)] (C and D), as well as surface expression and cleavage (E
and F) were quantified by densitometry and normalized to levels for WT HeV F. All
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data are represented as the means ± standard deviations for three independent
experiments. Statistical analyses were performed using a two-way analysis of
variance with a Bonferroni correction. Asterisks indicate statistical significance
compared to values for the WT HeV F (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 3.5. T483C/V484C and V484C/N485C are present over time at levels
that normally allow for fusion. (A) Vero cells were transfected with WT HeV F or
one of the TMD mutants. At 24 h posttransfection, the cells were metabolically
labeled for 30 min. Following different chase time points, the samples were
immunoprecipitated and analyzed by 10% SDS-PAGE. (B) Expression was
quantified by densitometry and normalized to the value for WT HeV F at each time
point. All data are represented as the means ± standard deviations for three
independent experiments.
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Figure 3.6. The introduced disulfide bonds in the HeV F TMD mutants are
poorly accessible to reducing agent. (A) The samples were prepared as
described in the legend of Fig. 3B, except the overlay medium consisted of BSRs
in DMEM plus 10% FBS ± 6 mM TCEP. Results were normalized to levels of the
samples transfected with WT HeV F and G (untreated). All data are presented as
the means ± standard deviations for three independent experiments. Statistical
analysis was performed using two-way analysis of variance with a Bonferroni
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correction. Asterisks indicate statistical significance compared to the level of the
WT HeV F+G (untreated) (***, P < 0.005). (B) The samples were prepared as
described in the legend of Fig. 2A, except that the samples were treated with
DMEM plus 10% FBS ± 6 mM TCEP for 3 h following the metabolic label. Blue
asterisks indicate trimer (F1), purple asterisk indicates dimer (F1), and orange
asterisks indicate monomer (F1).

61

Figure 3.7. T483C/V484C and V484C/N485C bind a prefusion conformationspecific antibody prior to cell disruption. (A) Vero cells were transfected with
WT HeV F or one of the TMD mutants. At 24 h posttransfection, the cells were
metabolically labeled for 24 h. Then, the cells were treated with HeV F MAb 5B3
antibody for 1 h, followed by lysis and pulldown. Control samples were lysed after
the overnight label and treated with HeV F anti-peptide Ab for immunoprecipitation.
The samples were analyzed by 10% SDS-PAGE. (B) 5B3 binding was quantified
by densitometry and normalized to the level of WT HeV F. All data are represented
as the means ± standard deviations for three independent experiments. (C) Vero
cells were transfected with WT HeV F or one of the TMD mutants. At 24 h
posttransfection, the cells were metabolically labeled for 3 h. Then, the samples
were immunoprecipitated with anti-peptide Ab or MAb 5B3 and analyzed by 10%
SDS-PAGE.
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Chapter 4: Human Metapneumovirus Replication Proteins Phase Separate
to Form Liquid-like Inclusion Bodies
Introduction
Human metapneumovirus (HMPV), which was discovered in 2001, is a
leading cause of severe respiratory tract infections in infants, the elderly, and
immunocompromised individuals (140). Five to twenty percent of hospitalizations
from respiratory infections in young children are due to HMPV (141, 142).
Symptoms of HMPV infection are similar to respiratory syncytial virus (RSV) and
include fever, cough, rhinorrhea, croup, bronchiolitis, pneumonia, and asthma
exacerbation (143). HMPV and RSV are members of the Pneumoviridae family
which was created in 2016 and classified within the Mononegavirales order (42).
Currently, no vaccines or antiviral treatments are approved to treat HMPV
infections, so most patients are managed with supportive care (143). The recent
discovery of HMPV highlights the need to understand the basic mechanisms of its
infectious life cycle. Specifically, analyzing the process of HMPV replication may
be crucial for identifying new targets for antiviral development.
Along with the pneumoviruses HMPV and RSV, other disease-causing
pathogens within the Mononegavirales order include Ebola virus, measles virus
(MeV), and rabies virus (RABV), which have negative-sense, single-stranded RNA
genomes. Though these viruses are classified within different families, they have
all been reported to form membrane-less cytoplasmic structures within infected
cells known as inclusion bodies (IBs) (58, 59, 61, 64). For some negative-sense,
single-stranded viruses, including HMPV, IBs have been shown to house active
viral replication and transcription (56, 57, 66-73). These processes involve several
viral proteins, such as the large polymerase (L), phosphoprotein (P), and
nucleoprotein (N). Further analysis of these structures has shown that RSV, MeV,
RABV, and vesicular stomatitis virus (VSV) IBs possess the properties of liquid
organelles formed via liquid-liquid phase separation (LLPS) (66, 85-88). LLPS is a
biophysical process by which a homogenous fluid separates into two distinct liquid
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phases (81). Phase separation plays a role in the formation of a variety of
membrane-less cellular compartments, such as processing bodies (P-bodies),
stress granules, and nucleoli, to concentrate specific proteins and nucleic acids,
particularly RNA (83). Properties that define these structures as liquid organelles
include the ability to undergo fusion and fission, rapid diffusion of internal contents,
and a spherical shape due to surface tension (144). Though LLPS has been shown
to play a role in the formation of IBs for some viruses, the physical mechanisms
and materials that mediate this process in the viral life cycle are still poorly
understood.
For RSV, HMPV, MeV, and RABV, the minimum viral components required
to reconstitute IB-like structures in cells are the N protein, which encapsidates the
RNA genome, and the P protein, which acts as a cofactor to mediate interactions
between the nucleoprotein and polymerase (65, 66, 75, 86). VSV also requires the
presence of the L protein with the N and P proteins to form IBs (85).These findings
suggest that interactions between the N and P proteins regulate phase separation
to form IBs as a structural platform for viral replication and transcription. Most
studies thus far have focused on cellular experiments to investigate viral IB liquid
dynamics, but recent publications on MeV and RSV have shown the importance
of utilizing purified protein systems to analyze interactions between the N and P
proteins in vitro (87, 88) . For MeV, the purified P protein and monomeric N protein
failed to phase separate independently but formed liquid droplets when mixed,
similar to the requirements for IB formation observed in cells. Interestingly, when
RNA was added to MeV N/P liquid droplets, it incorporated into the droplets and
led to the formation of nucleocapsid-like particles that were detected by electron
microscopy (87). In vitro experiments with RSV proteins showed that RNA-bound
N protein rings and P protein form phase separated liquid droplets when combined
in solution (88). These findings support the model that viral IBs form via LLPS, and
this mechanism is highly dependent upon interactions between the N and P
proteins. This process may enhance viral replication transcription for RSV.
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This is the first report to analyze phase separation for HMPV IBs. The HMPV
life cycle begins with the virus attaching and fusing to a target cell to release its
nucleocapsid into the cytoplasm with the associated replication proteins. The
nucleocapsid structure protects the genome from host nucleases and acts as a
template for the L protein. The genome is used to generate viral mRNA transcripts
that are translated by the host cell ribosomal machinery. The genome is also
replicated to make antigenome copies that can then be used to generate more
negative-sense genome to package into new virions. The P protein acts as an
adaptor to regulate interactions between the polymerase and RNA template during
transcription and replication. It functions as a tetrameric protein, in which the
monomers interact through a central oligomerization domain (84, 145). The
oligomerization domain is flanked by large intrinsically disordered regions (IDRs)
that give HMPV P the ability to interact with a variety of binding partners (84). For
instance, the C-terminus of the P protein interacts with RNA-bound N protein to
chaperone attachment to the polymerase. Additionally, HMPV P maintains a
monomeric pool of unbound N protein (N0) through an interaction involving the
HMPV P N-terminus with the C-terminal domain of the N protein (47). The
monomeric N0 protein can then be used for nucleocapsid assembly at sites of
replication where the polymerase synthesizes nascent RNA (47). HMPV P also
recruits the antitermination factor M2-1 to the polymerase during transcription to
bind nascent viral mRNA (99). Beyond transcription and replication, HMPV P has
been shown to play a role in direct cell-to-cell spread of infection by interacting with
actin, or an actin-binding protein, to reorganize the host cell cytoskeleton (76).
During HMPV infection, incoming and newly synthesized nucleocapsids
concentrate together in the cytoplasm in an actin-dependent manner (56, 74).
Eventually, the coalescence of these structures induces the formation of IBs where
viral RNA, viral mRNA, P protein, and N protein are detected (56). Inhibition of
actin polymerization was shown to significantly reduce HMPV viral transcription
and replication, suggesting that IB coalescence enhances the efficiency of these
processes (56). Recent work from our lab has shown that HMPV IBs are dynamic
structures that undergo fusion and fission in cells (Cifuentes-Muñoz, unpublished
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data). In addition, fluorescence recovery after photobleaching (FRAP) analysis has
shown that the internal contents of HMPV IBs have diffusion rates consistent with
other membrane-less compartments (El Najjar, unpublished data). Together, these
results support the characterization of HMPV IBs as liquid organelles formed by
LLPS.
Here we utilize a purified protein system to analyze LLPS of HMPV proteins
in vitro to support the characterization of HMPV IBs as liquid organelles and to
determine the interactions required for phase separation. We report that HMPV N
and P undergo phase separation and colocalize within liquid droplets when they
are mixed in solution. In contrast to MeV and RSV, the HMPV P protein undergoes
phase separation in the absence of other protein binding partners in vitro. RNA
localizes to HMPV P liquid droplets, providing the first evidence that HMPV P
interacts directly with RNA. A heparin purified N0-P construct, consisting of fulllength N protein linked to the first 40 amino acids of P, also phase separated
independently. However, combining N0-P with RNA led to the formation of solid
aggregates, suggesting that the addition of RNA promotes a liquid-to-solid
transition. WT RNA-bound N protein rings formed aggregates in solution but
incorporated into liquid droplets in the presence of P protein. These findings
suggest that HMPV P acts as a scaffold protein to support multivalent interactions
with HMPV N to promote phase separation of IBs.

Results
HMPV P phase separates independently in vitro
Since the HMPV N and P proteins are the minimum requirements needed
to form IB-like structures in eukaryotic cells, recombinant versions of the proteins
were expressed in E. coli and purified for in vitro analysis. Full-length, His6-tagged
HMPV P was purified by immobilized metal affinity chromatography (IMAC)
followed by anion exchange chromatography. Purified HMPV P was then tested in
the presence of the crowding agent dextran to assess its ability to undergo LLPS.
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LLPS is typically driven by scaffold proteins with specific features that promote
multivalent interactions with other proteins or RNA (80, 146, 147). HMPV P, which
includes long IDRs and alternating charged regions, fits the criteria of an LLPS
scaffold protein (84). Unlike the reports for MeV and RSV, purified HMPV P formed
liquid droplets independently that were visualized using differential interference
contrast (DIC) microscopy (FIG 4.1A). Time lapse imaging of the HMPV P droplets
showed that they underwent fusion, consistent with the idea that they possess a
liquid nature (FIG 4.1B). A turbidity assay was also used to analyze purified HMPV
P phase separation. The absorbance of the purified HMPV P protein solution was
measured at 395 nm at different time points to detect LLPS. The measurements
showed a peak for the absorbance above 0.12 between two and four hours,
supporting the microscopy imaging results that HMPV P phase separates in the
absence of other protein binding partners (FIG 4.1C).
Interactions with nucleic acid modulate HMPV P phase separation dynamics
Using the protein purification protocol described above, we noticed that the
A260/280 ratio was around 1.08, suggesting that the HMPV P protein sample was
interacting with nucleic acid. Since nucleic acids are known to play a role in LLPS,
we utilized an alternative purification protocol to determine if removing the nucleic
acid would influence HMPV P liquid droplet formation. The alternative protocol
included treatment with Benzonase nuclease and a IMAC purification step followed
by a heparin affinity column purification. This method was successful in removing
some of the nucleic acid as indicated by the decreased A260/280 ratio of 0.85.
Interestingly, DIC microscopy analysis showed that the recombinant HMPV P
protein purified by our alternative protocol formed liquid droplets more robustly
than the original protein sample (FIG 4.2A). In addition, time lapse imaging
analysis showed that the liquid droplets were capable of fusing (FIG 4.2B).
Turbidity assay results for the heparin purified HMPV P protein were similar to
previous samples, with a peak above 0.12 between two and four hours (FIG 4.2C).
These results suggest that the presence of increased levels of nucleic acid
modulate HMPV P phase separation dynamics.
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Charge interactions are known to influence phase separation and nucleic
acid binding, so both versions of purified HMPV P (anion exchange purified and
heparin purified) were analyzed for liquid droplet formation using buffers with
different concentrations of potassium chloride (KCl) ranging from 0 to 500 mM. For
the anion exchange purified HMPV P, liquid droplets were easily detected between
150 and 250 mM KCl. However, droplet formation was inhibited at concentrations
below or above that range (FIG 4.3A). For the heparin purified HMPV P, the largest
droplets formed at 150 mM KCl (maximum droplet size >50 µm). However, unlike
the anion exchange purified sample, liquid droplets formed for all the KCl buffers
tested (FIG 4.3A). This result suggests that HMPV P protein samples containing
higher levels of nucleic acid are more sensitive to changes in charge, thus leading
to the disruption of liquid droplet formation in vitro.
The differences we observed for anion exchanged purified and heparin
purified HMPV P led us to hypothesize that the multifunctional HMPV P protein
also possesses the ability to bind RNA. Given that 35 percent of the HMPV P
sequence consists of charged amino acids, it is not surprising that contaminating
RNA from E. coli may bind to HMPV P during the expression and purification
process (84). Based on our idea that HMPV P serves as a scaffold protein to drive
phase separation and recruit other viral components to IBs, we tested purified
HMPV P with a fluorescently tagged RNA oligomer to determine if RNA would
localize to the liquid droplets. Fluorescence imaging showed that the RNA oligomer
was incorporated into HMPV P liquid droplets, suggesting that the P protein may
play a role in binding to viral RNA within IBs to facilitate replication and transcription
(FIG 4.3B).
HMPV P recruits N0-P to liquid droplets
WT HMPV N spontaneously oligomerizes and binds to nonspecific RNAs
during standard purification procedures. Thus, we generated a recombinant N0-P
construct that includes full-length N (1-394) fused to a P peptide (1-40) to maintain
N in a monomeric, RNA-free form for purified protein analysis (FIG 4.4A) (47). Like
our approach with HMPV P, the N0-P construct was purified by two different
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methods to assess the effects of nucleic acid contaminants on our in vitro LLPS
system. The first procedure included an IMAC purification, and the alternative
procedure included both IMAC and heparin purification steps. Though the N0-P
protein purified by IMAC alone contained few protein contaminants, we were able
to successfully reduce the nucleic acid level with the addition of a heparin
purification step, as indicated by the A260/280 ratio of 0.6.
The N0-P construct purified by IMAC alone formed gel-like droplets that
were visualized by DIC microscopy (FIG 4.4B). Unlike the HMPV P liquid droplets,
the gel-like HMPV N0-P droplets remained partially undissolved in high salt
concentrations (data not shown). Over time, these gel-like droplets aggregated
together but did not undergo fusion (FIG 4.4B). In agreement with our microscopy
results, turbidity assays performed with the IMAC purified N0-P protein gave high
absorbance readings that peaked above 0.6, further indicating that the gel-like
droplets were aggregating in solution (FIG 4.5C). The subsequent drop in
absorbance suggests that the gel-like droplets settled to the bottom of the 96-well
plate.
The N0-P construct was tested with anion exchange purified HMPV P using
a droplet assay to determine if the P protein could influence N0-P dynamics in
solution. Our DIC and fluorescence microscopy analyses showed that mixing the
two constructs together led to enhanced LLPS as indicated by the presence of
larger and more numerous droplets than we previously observed for HMPV P
alone. The results showed that N0-P and P were incorporated into the same liquid
droplets, as indicated by the colocalization of the fluorescent signals used to label
the proteins (FIG 4.5A). In addition, the phase separated droplets underwent fusion
events (FIG 4.5B). A turbidity assay was utilized to determine if combining N0-P
with P affected the absorbance of the solution. The results showed that compared
to N0-P alone, the combination of N0-P and P led to lower absorbance readings
that peaked around 0.3 at two hours (FIG 4.5C). Together, these findings support
that HMPV P facilitates interactions with N0-P to recruit the protein into liquid
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droplets, and interactions between the proteins prevent the N0-P construct from
transitioning to a gel-like state.
The N0-P construct that was alternatively purified by IMAC and heparin was
also analyzed using our in vitro system. Unlike the N0-P protein purified by IMAC
alone, the heparin purified N0-P formed liquid droplets in the absence of other
protein binding partners (FIG 4.6A). Time lapse imaging of the heparin purified N0P droplets showed that they could fuse to form larger droplets (FIG 4.6B). Since
the removal of contaminating nucleic acids had a dramatic effect on N0-P LLPS
dynamics, we tested the heparin purified N0-P with a fluorescent RNA oligomer to
determine if the addition of nucleic acid would influence droplet formation.
Fluorescence microscopy imaging showed that the RNA oligomer disrupted N0-P
liquid droplet formation, leading to the formation of non-fusing aggregates (FIG
4.6C). These results suggest that RNA interactions inhibit N0-P LLPS dynamics,
causing the liquid droplets to transition to a gel-like or solid-like state.
HMPV P recruits N-RNA rings to liquid droplets
In addition to the monomeric N0-P construct, WT N-RNA rings were purified
for LLPS analysis in the presence or absence of HMPV P. DIC imaging of N-RNA
rings in the droplet assay showed the formation of aggregates, suggesting that this
protein-RNA complex does not phase separate independently (FIG 4.7A).
Combining the purified N-RNA rings with heparin purified HMPV P resulted in the
N-RNA complex being incorporated into liquid droplets (FIG 4.7B). The N-RNA/P
droplets (maximum droplet size = 6 µm) were generally smaller than the P alone
droplets (maximum droplet size = 11 µm), suggesting that this combination
influences phase separation dynamics. The influence of HMPV P on N-RNA for
liquid droplet formation was reflected in the turbidity assay results which showed
a lower peak for absorbance around 0.2 at two hours, compared to the absorbance
for N-RNA alone (FIG 4.7D).
HMPV P and N-RNA were tested in our in vitro system at different ratios to
determine the conditions that were required for N-RNA to be recruited to liquid
droplets. Though N-RNA aggregates were still present at 4:1 and 2:1 ratios of N70

RNA/P, liquid droplets were easily detected at a 1:1 ratio. The number and size of
the liquid droplets increased in samples with a higher proportion of HMPV P (1:2
and 1:4) (FIG 4.7C). These results suggest that a minimum threshold for the P
protein concentration must be met before N-RNA is induced to phase separate into
droplets. Liquid droplets containing HMPV P and N-RNA were also shown to
incorporate a fluorescent RNA oligomer (FIG 4.7E). These findings highlight that
HMPV P, N, and RNA form complex multivalent interactions to promote phase
separation and to support the structure of IBs required to enhance replication and
transcription.

Discussion
IB formation has been reported for many negative-strand viruses across
different families in the Mononegavirales order (148). An increasing wealth of
evidence supports that these structures function as viral factories by concentrating
the machinery and materials required for replication and transcription. Cellular
studies of IBs have shown that these structures are membrane-less and dynamic,
which led to the characterization of IBs as liquid organelles. Though liquid
organelles have been recognized in the cell for many decades, scientists have only
recently linked the formation of these structures to the biophysical process of
LLPS. Understanding the role of LLPS in IB formation may be critical for
discovering new targets for antiviral development. Until now, no reports have been
published to identify HMPV IBs as phase separated liquid organelles. To analyze
the viral protein interactions driving this process, an in vitro system was utilized to
test recombinant versions of HMPV purified proteins.
We focused on purifying full-length P, N-RNA rings, and the monomeric N0P construct for in vitro analysis. Though the process of IB formation likely involves
many similarities for different negative-strand viruses, our analysis of HMPV
proteins led to the discovery of unique features that highlight differences among
these viral systems. We found that HMPV P phase separates independently in
vitro, supporting our hypothesis that the P protein is a scaffold which recruits other
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client proteins to liquid droplets to drive LLPS. Interestingly, our data also showed
that HMPV P incorporates RNA into liquid droplets. This suggests that the P
protein, which is known to bind several proteins involved in the replication process,
may also directly interact with RNA to facilitate phase separation and to enhance
viral replication. In addition to incorporating RNA, purified HMPV P also recruited
monomeric N0-P and oligomeric N-RNA rings to liquid droplets, further supporting
our model in which P serves as a scaffold for LLPS. This is the first report to
highlight a negative-strand virus P protein as the independent driver of phase
separation. Additionally, this work provides the first evidence for a previously
undescribed role of HMPV P for interacting directly with RNA. Together, these
findings provide important information for understanding the formation of HMPV
IBs that may be applicable to other negative-strand viruses.
Our previous studies of HMPV IBs showed that these structures contain
viral positive-sense RNA and genomic RNA along with the N and P proteins.
However, other viral proteins, such as the fusion protein and matrix protein, are
generally excluded from IBs (56). The contents of HMPV IBs suggested that these
structures were likely involved in housing viral replication and transcription,
whereas assembly steps appeared to occur outside of IBs. We highlighted that the
cellular actin network plays a role in bringing small IBs together to form larger
membrane-less structures. In addition, we confirmed that IB formation and
coalescence is critical for promoting efficient replication and transcription (56).
Other work from our lab has focused on late events in the HMPV life cycle to
understand assembly and spread. Interestingly, the HMPV P protein was shown
to extensively colocalize with actin and promote the formation of cellular
extensions for direct cell-to-cell spread of infection (76). A recent report from our
group utilizing three-dimensional human airway tissues to study HMPV infection
supported these findings related to viral replication and spread. HMPV-infected
human airway epithelial (HAE) cells showed the presence of IBs containing N
protein, P protein, and viral genomic RNA (149). Additionally, the HMPV-infected
HAE cells were shown to form actin-based filamentous extensions (149). These
results suggested that IB and extension formation are physiologically relevant
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processes used by HMPV to promote infection. HMPV extensions may provide a
route for transporting IB components to new cells to expedite the infection process.
The liquid-like nature of IBs may be critical for moving infectious materials through
narrow cell-to-cell extensions.
We hypothesized that the intrinsically disordered regions of HMPV P allow
it to interact with a variety of proteins to promote IB formation. Recently, a structure
was published for the HMPV polymerase/P protein complex (92). The cryoelectron microscopy structure showed that the P protein tetramer interacts
extensively with the N-terminal region of the polymerase. The central
oligomerization domain of HMPV P is anchored to the polymerase, and the Nterminal regions of P undergo a disorder-to-order transition upon binding to N0
(47). HMPV P may facilitate delivery of N0 to the RNA exit tunnel to encapsidate
nascent RNA. The C-terminal regions of P are asymmetrically oriented on the
polymerase to promote interactions with N-RNA, likely to dislodge the RNA and
deliver it to the entrance of the polymerase RNA tunnel (47, 92). The nonequivalent positions of the HMPV P C-terminal regions within the tetramer highlight
the importance of IDRs, which allow a protein to adopt a variety of conformations
(150). Like HMPV P, RSV P is also a tetrameric protein with a central
oligomerization domain flanked by long IDRs (151-154). A structure of the RSV
polymerase/P protein complex was published around the same time as the HMPV
structure. The RSV structure showed that each protomer of the P protein tetramer
adopts a different conformation in association with the polymerase (155). Similar
to HMPV, these results highlight the dynamic nature of the P protein which is
heavily influenced by the presence of large IDRs. Though some structural aspects
of P proteins differ among negative-strand RNA viruses, IDRs are a common P
protein feature across families (84, 90, 95, 145, 153, 154, 156, 157).
Features of HMPV P and other negative-strand virus P proteins, including
long IDRs, repetitive blocks of alternating charge, and phosphorylation sites, fit the
molecular signature of proteins that phase separate under physiological conditions
(83, 84). The propensity for HMPV P to mediate multivalent interactions and phase
73

separate independently in vitro suggests that it functions as a scaffold to regulate
LLPS for IB formation during infection (80). In contrast to our in vitro results, the
HMPV N and P proteins must be coexpressed in cells to generate IB-like structures
(65). Without HMPV N, the P protein shows diffuse cytoplasmic localization. This
difference between the cellular and in vitro systems suggests that host factors
present in the cytoplasm may block HMPV P interactions required to induce LLPS.
However, coexpression of HMPV P and N likely creates more opportunities for
multivalent protein-protein and protein-RNA interactions to concentrate enough IB
components to drive phase separation. LLPS is a highly sensitive process that
depends on a number of factors such as protein/RNA concentration, salt content,
pH, and temperature (83). Thus, one or more of these factors in cells may prevent
HMPV P from phase separating when expressed on its own. Our findings highlight
notable contrasts between cellular and in vitro studies of HMPV IBs, suggesting
that in vitro work must be carefully analyzed before applying conclusions to live
virus systems. Though cellular and in vitro IB studies are both crucial for
understanding HMPV replication, further analysis is needed to bridge the gap
between these bodies of work.
Reports on MeV and RSV IBs have utilized a similar in vitro system to
analyze phase separation dynamics of purified proteins (87, 88). MeV IBs were
first characterized as liquid organelles by analyzing the structures in infected or
transfected cells (86). Analysis of MeV IBs during infection showed that the
structures are initially spherical, but they become large and irregularly shaped at
later time points of infection. In transfected cells, MeV N and P are sufficient to
mediate IB-like structure formation, with the C-terminal domains of both proteins
being critical for phase separation. However, MeV P expression alone induced the
formation of perinuclear puncta, which were rarely spherical and very large, in 35
percent of transfected cells. This suggests that MeV P may promote multivalent
interactions under specific cellular conditions to form these structures (86). MeV in
vitro studies showed that a combination of the N and P proteins was required to
induce droplet formation. The minimum N and P domains needed for droplets to
form were also reported: full-length N protein bound to a 50 amino acid N-terminal
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P peptide (P50) and P304-507, which includes the tetramerization domain, intrinsically
disordered Ploop, and C-terminal three-helix bundle (XD) (87). Contrasting LLPS
results observed for MeV and our HMPV system may be due to differences in the
P protein structures. For instance, MeV P is 213 amino acids longer than HMPV P
and includes the folded XD domain after the unfolded Ploop.
A recent report on RSV used both cellular and in vitro analysis to
characterize RSV IBs as liquid organelles formed via LLPS. Deletion of the Nterminal IDR of RSV P did not impact IB-like structure formation in cells, but the
oligomerization domain and C-terminal IDR were required (88). This was
supported by in vitro results which showed that the N-terminal domain was
dispensable, but the C-terminal domain and oligomerization domain were required
for liquid droplet formation with N-RNA. They also showed that a higher ratio of
RSV P to N-RNA was needed to detect liquid droplet formation, whereas we
observed that HMVP N-RNA/P droplets were easily detected at a 1:1 ratio (88).
Compared to HMPV P, RSV P is 53 amino acids shorter, though the domain
organization is similar for both. The differences observed for these viral systems
highlight that LLPS is highly dependent on multivalent interactions mediated by the
P protein, and these interactions are influenced by the unique composition of the
P protein. Additional analysis of specific HMPV N and P protein domains will be
beneficial for determining which domains are critical for phase separation and IB
formation.
The RSV and MeV reports also analyzed the importance of interactions
between the N protein and RNA for LLPS. An RNA-binding mutant of MeV N still
formed IB-like structures with P protein in cells, suggesting that N/RNA interactions
are not required for IB formation (86). The minimal MeV LLPS in vitro system was
also used to show that RNA diffuses into MeV N/P liquid droplets, triggering the
formation of nucleocapsid-like particles (87). The rate of particle assembly was
significantly increased compared to non-phase separating conditions. These
findings suggest that RNA is not required for N/P droplet formation, but IBs serve
to enhance the efficiency of nucleocapsid assembly during infection. Incorporation
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of RNA into HMPV P droplets in our system highlights that HMPV may utilize IB
formation in a similar manner to facilitate nucleocapsid assembly. A monomeric,
RNA-free RSV N protein mutant was unable to form IB-like structures with WT P
protein in cells, suggesting that RSV N must oligomerize and bind RNA to mediate
IB formation (88). However, our in vitro results with HMPV N0-P suggested that
oligomerization and RNA interactions are not required for phase separation. An in
vitro analysis of HMPV and RSV N RNA-binding mutants would be useful for
further analyzing the role of RNA interactions and oligomerization in LLPS. Though
the structures of RSV N and HMPV N are quite similar, small differences may have
a dramatic impact on the weak multivalent interactions with HMPV P that drive
LLPS.
In conclusion, we showed that HMPV P acts as a scaffold for in vitro phase
separation to recruit monomeric N protein, oligomerized N protein, and RNA to
liquid droplets. These results support our cellular analysis of HMPV IBs, in which
we have described IBs as dynamic, membrane-less structures that coalesce
throughout infection. These findings support the hypothesis that many negativestrand viruses of the Mononegavirales order have evolved mechanisms to utilize
LLPS for IB formation to promote efficient replication and transcription. Our results
support that the large IDRs of HMPV P allow for the protein to phase separate
independently and recruit other proteins to liquid droplets. Research from our lab
has shown that HMPV P is phosphorylated in cells (Thompson, unpublished data).
Phosphorylation and other post-translational modifications have been shown to
play a role in phase separation. Thus, additional in vitro and cellular studies of
HMPV P will be important for elucidating the effects of phosphorylation and
dephosphorylation events. Work on HMPV should also continue to define the
domains of the N and P proteins required for phase separation. Finally, further
work on HMPV P to understand how it recruits RNA to liquid droplets will be critical
for characterizing its role in LLPS. Overall, the findings presented here build on the
foundation for understanding the formation of IBs and the mechanisms that
regulate LLPS for negative-strand virus proteins.
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Figure 4.1 Anion exchange purified HMPV P phase separates independently
in vitro. (A) Anion exchanged purified HMPV P was tested at concentrations
ranging from 5 µM to 50 µM in a droplet assay (maximum droplet size = 3.4 µm).
DIC microscopy imaging of droplets was performed with a 60X objective on a
Nikon Eclipse E600. The scale bar is 10 µm. (D) Time lapse imaging of anion
exchange purified HMPV P (80 µM) droplet fusion was acquired using a 100X oil
objective on a Zeiss Axiovert 200M microscope. (C) Anion exchange purified
HMPV P (40 µM) was mixed with turbidity assay buffer in a clear 96-well plate. The
solution was analyzed using a SpectraMax iD3 to measure the absorbance at 395
nm at 5 min intervals with mixing.
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Figure 4.2. Heparin purified HMPV P phase separates independently in vitro.
(A) Heparin purified HMPV P was tested at concentrations ranging from 5 µM to
50 µM in a droplet assay (maximum droplet size >50 µm). DIC microscopy imaging
of droplets was performed with a 60X objective on a Nikon Eclipse E600. The scale
bar is 10 µm. (B) Time lapse imaging of heparin purified HMPV P (150 uM) droplet
fusion was acquired using a 100X oil objective on a Zeiss Axiovert 200M
microscope. (C) Heparin purified HMPV P (40 µM) was mixed with turbidity assay
buffer in a clear 96-well plate. The solution was analyzed using a SpectraMax iD3
to measure the absorbance at 395 nm at 5 min intervals with mixing.
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Figure 4.3. Interactions with nucleic acid modulate HMPV P phase separation
dynamics. (A) Anion exchange purified HMPV P (15 µM) and heparin purified
HMPV P (15 µM) were tested in a droplet assay using buffers with different
concentrations of KCl ranging from 0 mM to 500 mM. DIC microscopy imaging of
droplets was performed with a 60X objective on a Nikon Eclipse E600. The scale
bar is 10 µm. (B) Heparin purified HMPV P (15 µM) was tested in a droplet assay
with an RNA decamer tagged with 6-carboxyfluorescein on the 3’ end (5 µM). The
DIC and fluorescence images were acquired with a 60X objective on a Nikon
Eclipse E600. The scale bar is 10 µm.

79

Figure 4.4 IMAC purified N0-P forms gel-like droplets that aggregate over
time. (A) Schematic of the N0-P construct which includes full-length HMPV N fused
to the first 40 amino acids of HMPV P. (B). IMAC purified HMPV N0-P (15 µM)
labeled with Alexa 488 TFP ester was tested in a droplet assay. DIC and
fluorescence images were acquired at different time points using a 60X objective
on a Nikon Eclipse E600. The scale bars are 10 µm.
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Figure 4.5. HMPV P recruits N0-P to liquid droplets. (A) IMAC purified HMPV
N0-P (15 µM) labeled with Alexa 488 TFP ester was mixed with anion exchange
purified HMPV P (15 µM) labeled with Alexa 594 NHS ester in a droplet assay.
Fluorescence images were acquired using a 60X objective on a Nikon Eclipse
E600. The scale bar is 10 µm. (B) IMAC purified HMPV N0-P (50 µM) was mixed
with anion exchange purified HMPV P (50 µM). Time lapse imaging of N0-P/P
droplet fusion was acquired using a 100X oil objective on a Zeiss Axiovert 200M
microscope. (C) IMAC purified HMPV N0-P (40 µM) was tested alone or with anion
exchange purified HMPV P (40 µM) in a turbidity assay. The protein solutions were
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plated in a clear 96-well plate with turbidity assay buffer, and the absorbance was
measured at 395 nm by a SpectraMax iD3 at 5 min intervals with mixing.
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Figure 4.6. Heparin purified HMPV N0-P phase separates independently in
vitro. (A) Heparin purified HMPV N0-P was tested at concentrations ranging from
5 µM to 50 µM in a droplet assay. DIC microscopy imaging of droplets was
performed with a 60X objective on a Nikon Eclipse E600. The scale bar is 10 µm.
(B) Time lapse imaging of heparin purified HMPV N0-P (80 µM) droplet fusion was
acquired using a 100X oil objective on a Zeiss Axiovert 200M microscope. (C)
Heparin purified HMPV N0-P (15 µM) was tested in a droplet assay with an RNA
decamer tagged with 6-carboxyfluorescein on the 3’ end (5 µM). The DIC and
fluorescence images were acquired with a 60X objective on a Nikon Eclipse E600.
The scale bar is 10 µm.

83

Figure 4.7. HMPV P recruits N-RNA rings to liquid droplets. (A) HMPV N-RNA
(25 µM) was tested in a droplet assay. DIC microscopy imaging of droplets was
performed with a 60X objective on a Nikon Eclipse E600. The scale bar is 10 µm.
(B) HMPV N-RNA (15 µM) was mixed with heparin purified HMPV P (15 µM) in a
droplet assay. DIC images were acquired using a 60X objective on a Nikon Eclipse
E600. The scale bar is 10 µm. (C) HMPV N-RNA and heparin purified HMPV P
were tested in a droplet assay at different ratios (4:1 = 20 µM N-RNA: 5 µM P; 2:1
= 10 µM N-RNA: 5 µM P; 1:1 = 5 µM N-RNA: 5 µM P; 1:2 = 5 µM N-RNA: 10 µM
P; 1:4 = 5 µM N-RNA: 20 µM P). DIC microscopy imaging of droplets was
performed as described above. (D) HMPV N-RNA (40 µM) was tested alone or
with heparin purified HMPV P (40 µM) in a turbidity assay. The protein solutions
were plated in a clear 96-well plate with turbidity assay buffer, and the absorbance
was measured at 395 nm by a SpectraMax iD3 at 5 min intervals with mixing. (E)
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HMPV N-RNA (15 µM), heparin purified HMPV P (15 µM), and an RNA decamer
tagged with 6-carboxyfluorescein on the 3’ end (5 µM) were mixed and tested in a
droplet assay. DIC and fluorescence microscopy imaging of droplets was
performed as described above. The scale bar is 10 µm.
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Chapter 5: Discussion and Future Directions
Overview
The work presented here builds on our current understanding of viral fusion
events, replication, and inclusion body (IB) formation for viruses within the
Mononegavirales order. Specifically, these findings elucidate previously unknown
aspects of the viral life cycle for paramyxoviruses and pneumoviruses. Many
studies on viral entry have focused on the membrane glycoprotein that promotes
fusion with a target cell membrane. Cellular protein experiments and structural
analysis of viral particles and proteins have provided a platform for determining the
conformational changes in the glycoprotein that regulate the fusion event. Our
group has focused its work on the transmembrane domain (TMD) of the Hendra
virus (HeV) fusion protein (F) to determine how interactions in this region regulate
fusion dynamics. We found that the TMDs of the HeV F trimer must dissociate to
allow for conformational changes within the protein that lead to membrane fusion
(Chapter 3). After analyzing this early step in the viral life cycle, we addressed
questions regarding subsequent steps in the cycle that occur in the host cell
cytoplasm. Many negative-strand viruses produce cytoplasmic IBs for replication
and transcription, but numerous questions remain unanswered regarding how IBs
form and function. We built on our previous work with human metapneumovirus
(HMPV) to analyze the mechanisms regulating IB formation to understand how
they promote replication and transcription. We discovered that the HMPV
phosphoprotein (P) plays a critical role in mediating IB formation via the process
of liquid-liquid phase separation (LLPS) (Chapter 4). These studies on HeV and
HMPV shed light on the complex protein interactions that govern fusion protein
triggering, IB coalescence, and replication/transcription events. In addition, they
illuminate new questions that must be answered to identify novel targets for
therapeutic development.
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HeV entry
Determining HeV F TMD interactions
Analysis of the HeV F TMD sequence is important for understanding the
interactions that contribute to trimerization as well as dissociation once the F
protein is triggered. One sequence motif that has been shown to enhance TMD
interactions in different proteins is GXXXG. The HeV F TMD includes an AXXXG
motif, and mutation of the glycine residue decreased cell surface expression,
suggesting that prefusion HeV F stability was reduced (40). Sedimentation
equilibrium analysis was also used to determine the effects of mutating this TMD
glycine residue. The results showed that mutating the glycine to alanine led to a
moderate increase in TMD interactions, whereas mutating glycine to leucine or
isoleucine led to even stronger TMD association (40). This suggested that the
G508 residue was not the only factor driving TMD interactions in HeV F, since
other residues must be responsible for maintaining the F protein trimer. Further
work addressed the presence of polar residues in the TMD because cooperative
interaction of polar residues has been associated with transmembrane helix
packing. Mutation of HeV F TMD polar residues to alanine showed that protein
folding was impacted and stability was reduced, suggesting that these polar
residues are required for proper TMD interactions (40).
In addition to stabilizing the prefusion conformation, some HeV F TMD
residues are important for endocytic recycling. This process is crucial so that the
precursor F0 can be cleaved to form the disulfide-linked heterodimer F1+F2, which
can actively participate in fusion events. Compared to other TMDs, the HeV F TMD
contains many noncharged polar residues (158). Two polar amino acids, S490 and
Y498, in the HeV F TMD were shown to be important for proper HeV F trafficking.
S490, which sits close to the ectodomain of HeV F in the N-terminal region of the
TMD, is important for HeV F endocytosis. Specifically, the serine hydroxyl group is
required for proper trafficking. Hydrogen bonds between this hydroxyl group and
other side chains likely influence this process. Y498 is required for efficiently
recycling HeV F to the surface after processing, and the aromatic ring, rather than
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the hydroxyl group, promotes the interactions which allow for this event (28). The
S490 and Y498 residues are also found in the TMD of the Nipah virus (NiV) F
protein, suggesting that they are crucial for NiV F endocytosis and recycling events
as well (28). This work further expanded our understanding of the importance of
TMD interactions for critical HeV F functions.
The sequence of the HeV F TMD was compared to other paramyxovirus F
protein TMD sequences to analyze similarities that could govern TMD interactions.
Evaluation of 140 sequences led to the identification of a β-branched heptad
repeat. Specifically, the HeV F TMD was shown to possess a heptad repeat
leucine-isoleucine zipper, a motif which promotes oligomerization in a hydrophobic
environment (114). Mutation of the leucine-isoleucine zipper reduced stability of
the HeV F prefusion conformation. This suggests that TMD interactions promoted
by the leucine-isoleucine zipper are required to maintain the metastable prefusion
structure. In addition, results from this study suggested that TMD interactions play
a significant role in the triggering process (114). The leucine-isoleucine zipper
identified in the parainfluenza virus 5 (PIV5) F TMD was also mutated to determine
the effects on F protein expression, stability, and fusion (159). Unlike HeV F, the
mutations in the PIV5 F TMD only had modest effects on protein expression and
stability. However, the PIV5 F TMD leucine-isoleucine zipper was critically
important for fusogenic activity (159). Together, the work on HeV F and PIV5 F
support the findings described in Chapter 3, which emphasize the significance of
modulating TMD interactions to drive fusion. Overall, these findings highlight the
dynamic TMD interactions which impact the F protein as it folds, traffics, undergoes
processing, and triggers.
Targeting the viral F protein TMD
Though structural studies of HeV F and other F proteins have provided
crucial conformational data, cellular expression studies are particularly important
for further understanding the non-static conformational changes involved in F
protein triggering. The work presented in Chapter 3 supports previous studies
which showed that the TMD of HeV F has functional importance beyond anchoring
88

the protein in the viral membrane (41, 114). Specifically, the HeV F TMD
interactions are required to stabilize the prefusion form prior to triggering, and
changes in TMD interactions helps drive conformational refolding required for
fusion. In addition, work on enveloped virus F proteins has shown that substituting
the TMD region of one F protein into another can be detrimental for fusion activity,
further suggesting that TMD interactions play a specific role in promoting fusion
(160). Disrupting or prematurely triggering F proteins presents a potential
therapeutic target that could be applicable to numerous enveloped viruses.
Additional work was performed by our group to elucidate the role of TMD
interactions in HeV F conformational stability. Exogenous transmembrane
constructs mimicking the TMD of HeV F were expressed to determine if they could
disrupt TMD interactions in wild type (WT) HeV F (161). Results showed that the
transmembrane protein constructs reduced HeV F expression and fusion activity.
This concept was also applied to the paramyxovirus PIV5 to see if homologous
transmembrane constructs could block viral infection. Pretreatment of the virus
with the PIV5 TMD construct led to reduced viral infection in cells (161). This
suggests that TMD constructs or other peptides may be useful for targeting F
proteins to cause them to misfold or prematurely trigger. Further studies on
enveloped virus F proteins will be important for developing new therapies like this.
The role of the TMD in HeV F conformational changes
Work focused on TMD interactions and targeting the TMD has suggested
that this region of the HeV F protein is critical for numerous functions, including
fusogenic activity. To understand the factors that contribute to fusion events, we
considered the TMD interactions that might promote conformational changes in
the rest of the protein. The HeV F HRB forms a trimeric coiled coil, but isolated
HRB peptides do not associate together (162). This suggests that HeV F TMD
interactions are required to maintain the conformation of the HRB coiled coil prior
to triggering. Interactions in the ectodomain may also help to preserve the springlike HRB coiled coil. Our model, which is supported by data in Chapter 3, suggests
that triggering of HeV F involves dissociation of the TMDs. TMD dissociation likely
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modulates interactions within the HRB coiled coil, leading to further refolding of the
ectodomain. Dissociation of the TMDs is suggested to begin with the C-terminal
region where β-branched residues destabilize the alpha-helix (41). This localized
dissociation may then initiate separation of N-terminal TMD regions and
subsequently destabilize the HRB coiled coil.
In Chapter 3, we analyzed HeV F TMD mutants which were chemically
linked by disulfide bonds to prohibit dissociation of the TMD trimer. The double
cysteine substitutions were made at the N-terminal region of the TMD to promote
disulfide bond formation within the oxidizing environment of the endoplasmic
reticulum. Our results suggest that TMD dissociation was not necessary for proper
folding or trafficking of HeV F. However, fusion activity was completely abolished
for the mutants, suggesting that TMD dissociation is required for refolding of HeV
F. These findings support that TMD dissociation, which likely initiates at the Cterminal residues, must subsequently occur in the N-terminal TMD to allow for
fusion. Since the N-terminal TMD region is connected to the HRB domain,
dissociation of the N-terminal TMD residues may be the critical event which
immediately precedes destabilization of the HRB coiled coil. Further studies will
address the role of the N-terminal TMD residues in HeV F stability, trafficking, and
fusogenic activity.
The disulfide-linked HeV F TMD mutants were also tested with a prefusion
conformation-specific antibody, and results showed that cell lysis led to decreased
binding of the antibody, similar to WT HeV F which is triggered during cell
disruption. This suggests that the mutants were not locked in the prefusion
conformation and underwent some conformational changes. However, the
conformations adopted by the mutants due to cell lysis are unclear. Cell lysis may
alter interactions in the ectodomain, and the changes may be sufficient to
destabilize the HRB coiled coil without the need for TMD dissociation. Future work
should analyze the mutants to determine which conformational intermediates are
able to form when the TMDs are locked together. These studies will be important
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for elucidating the conformational changes that can occur in HeV F prior to TMD
dissociation.

Phase separation for viral replication
Phase separation of liquid organelles: Function and dysfunction
Identification of IBs and other membrane-less compartments as phase
separated condensates has generated many studies to understand how these
structures are regulated. Researchers are particularly interested in the functions
that emerge from organizing molecules into phase separated regions. For
instance, reports have shown that disruption of condensates does not usually
impact cell viability (80). However, the ubiquity of condensates in cells suggests
that they serve an important functional role (80, 83, 163, 164). For HMPV,
disruption of actin polymerization inhibited IB coalescence, leading to decreased
viral expression. However, expression was not completely abolished (56). In the
viral life cycle, any decrease in efficiency can be detrimental for the virus as it
combats the host cell immune system to produce new viral progeny. This idea
suggests that condensate formation may provide subtle enhancements in the
frequency of biochemical reactions which together benefit the overall function of
the cell or the invading pathogen.
Researchers have also been interested in LLPS and condensates due to
their role in neurodegenerative disease. Several proteins that are known to phase
separate have been shown to form pathological brain inclusions, leading to various
forms of neurodegeneration. One example is TDP-43, a stress granule protein
involved in mRNA processes such as splicing, transport, and translation regulation.
TDP-43 brain inclusions have been linked to a number of diseases including
Alzheimer’s, amyotrophic lateral sclerosis (ALS), and chronic traumatic
encephalopathy (165). Stress granules are known to form under certain conditions
and dissociate when the stressor is removed. TDP-43 and other stress granule
proteins can have pathological effects when mutations prevent disassembly of the
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condensates. When liquid organelles lose dynamicity and transition to a solid-like
state, they are generally unable to facilitate normal biochemical processes for the
cell. Continued research into LLPS of liquid organelles is critical to understand how
changes in protein-protein and protein-RNA interactions can drive condensates to
transition to an aggregated, solid-like state. This work may also impact our
knowledge of viral IB formation, since HMPV P modulates interactions with N-RNA,
which aggregates in solution, to incorporate it into liquid droplets. Determining the
mechanisms that drive phase transitions in liquid organelles and pathological
inclusions will provide critical knowledge for understanding the links between LLPS
and biomolecular condensates.
Maturation of IBs during infection
Though pathological inclusions transition to a solid-like state, it is normal for
condensates to mature over time due to their metastable nature (165).
Thermodynamically, larger droplets are more stable than smaller droplets, so
smaller droplets spontaneously dissolve as proteins diffuse into larger droplets.
This event, which is known as coarsening, is different from fusion events which
involve two smaller droplets coming together to form a larger droplet (165). As
coarsening occurs over time, droplets become less dynamic and mature to a gellike state. This process is thought to be driven in part by proteins with intrinsically
disordered regions (IDRs). Compared to pathological aggregates, which undergo
a rapid transition to a solid-like state, this maturation process is much slower and
can be reversed (165). A physical explanation for droplet maturation is interesting
in the context of viral IBs.
The liquid nature of IBs was initially described for rabies virus (RABV) Negri
bodies (66). RABV Negri bodies have been shown to incorporate a variety of
proteins including the P protein, nucleoprotein (N), polymerase, and matrix protein
(72, 166). In addition, the host proteins Hsp70 and focal adhesion kinase (FAK)
localize to Negri bodies (167, 168). Interestingly, FAK was shown to directly
interact with RABV P, and disruption of this interaction inhibited viral RNA
replication and viral protein expression (168). The Hsp70 chaperone directly
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interacts with RABV N and is suggested to be involved in viral transcription or
translation (167). These findings highlight the complex composition of Negri bodies
and their role in promoting efficient viral multiplication. Negri body formation was
characterized over time during RABV infection, and results showed that the
spherical structures grew over time and sometimes evolved into irregular shapes
(66). The later stage, nonspherical Negri bodies were often associated with
membranes. Observations of changes in the number, size, and shape of RABV
Negri bodies suggests that these liquid organelles undergo a maturation process
throughout infection. Characterizing the mechanisms that regulate Negri body
maturation will be important for illuminating their role in the viral life cycle.
Maturation of measles virus (MeV) IBs has also been observed during
infection (86). Until 12 hours post infection, MeV-infected cells showed the
presence of small spherical structures in the cytoplasm. At later time points, larger
IBs were observed, and some were irregularly shaped. The nonspherical
structures were often located near the nucleus (86). The irregular shape of later
stage IBs suggests that they transition to a less dynamic state over time. Like
RABV, the loss of spherical shape may be partly due an association with host cell
membrane components at later points of infection. Many positive-sense RNA
viruses are known to associate with membranes to generate replication complexes
(169). Thus, some negative-strand RNA viruses may also utilize membrane
components within IBs to enhance replication or another step of the viral life cycle.
HMPV and RSV infections show differences in the maturation IBs. As
HMPV infection progresses, the quantity of IBs was shown to modestly increase,
with only a few IBs generally found in each cell at late infection time points (56).
IBs tend to increase in size throughout infection, suggesting that they undergo
fusion events and mature as more protein diffuses into the structures. Even at late
time points, HMPV IBs typically retain a spherical shape, in contrast to the irregular
structures observed for MeV and RABV. For RSV, IBs contain substructures
known as IB-associated granules (IBAGs) (67). Newly synthesized viral mRNA and
the M2-1 protein localize to IBAGs, whereas the N, L, and P proteins as well as
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viral genomic RNA are excluded from these structures. These structures were
shown to develop within IBs by 12 hours post infection, suggesting that they form
as a result of IB maturation over time. IBAG formation within IBs was shown to be
dependent upon viral mRNA synthesis (67). The findings for RSV IBs suggest that
newly transcribed viral mRNAs are stored within IBAGs prior to release into the
cytoplasm. However, further studies are needed to understand the function of
IBAGs and the mechanisms that regulate maturation of these IB substructures.
Thus far, IBAGs have not been observed for any other negative-strand RNA
viruses.
In vitro analysis of HMPV proteins showed that heparin purified HMPV P
liquid droplets often contained round, dimple-like regions (FIG 5.1). In addition,
these dimple-like regions were also observed for liquid droplets containing HMPV
N-RNA and P (FIG 5.1). Additional analysis is needed to determine if the formation
of these regions is functionally important to liquid droplet formation. However, it is
interesting to speculate that HMPV proteins may induce interactions for LLPS that
lead to the formation of IB substructures, similar to the IBAGs observed for RSV.
Though the initial characterization of HMPV IB formation did not show the
presence of IB substructures, high resolution microscopy techniques may be
beneficial for identifying previously unrecognized features of IBs for different
viruses.
Liquid organelle maturation is also interesting in the context of the
monomeric HMPV N0-P construct that was purified for in vitro studies. As described
in Chapter 4, immobilized metal affinity chromatography (IMAC) purified HMPV N0P formed gel-like droplets which did not undergo fusion. However, adding a
heparin purification step allowed for N0-P to phase separate in the absence of other
binding partners. This suggests that nucleic acid contaminants in the IMAC purified
HMPV N0-P solution impact LLPS dynamics. Higher levels of nucleic acid may
increase the rate at which N0-P droplets transition from a liquid to gel-like state.
This is an interesting result since some viral IBs appear to become more gel-like
at late stages of infection (86). As the level of RNA increases within IBs during
replication and transcription, the RNA may drive the transition of IBs from liquid94

like to gel-like, leading to slower exchange of materials with the cytoplasm.
However, this maturation to a gel-like state likely involves modulation of numerous
factors in addition to RNA concentration.
The role of RNA-binding in phase separation
Different varieties of RNA-protein granules are a common example of liquid
organelles found in the cell. The presence of viral genomic RNA and viral mRNA
in IBs suggests that they possess similarities with other RNA-protein granules. In
Chapter 4, we reported that HMPV P recruited monomeric, RNA-free N protein and
oligomeric N-RNA rings to liquid droplets. This suggests that RNA interactions with
N protein are not required for phase separation with HMPV P. MeV work showed
that IB-like structures formed in cells when an N protein RNA-binding mutant was
cotransfected with MeV P (84). Additionally, recombinant MeV N protein purified
as a monomer phase separated with MeV P in vitro (87). However, RSV studies
suggested that N protein oligomerization and RNA-binding were required for IBlike structure formation with RSV P in cells (88). These varying results warrant
further work into the role of RNA-binding in viral protein phase separation.
In addition to our monomeric N0-P construct, we also purified a potential
HMPV N RNA-binding mutant, based on an RNA-free mutant described for RSV
(170). The RSV mutant N K170A/R185A was purified as a monomer and was
shown to lack the ability to bind RNA, based on the low A260/280 ratio of the
purified protein. After sequence comparison with RSV N, we designed HMPV N
K171A/R186A as a potential RNA-binding mutant to test in our purified protein
system. The construct was prepared using an IMAC purification step followed by
a heparin purification step. When HMPV N K171A/R186A was tested
independently in the droplet assay, it formed aggregates similar to N-RNA and
IMAC purified N0-P (FIG 5.2). Interestingly, HMPV N K171A/R186A was recruited
to liquid droplets when it was mixed with anion exchange purified HMPV P (FIG
5.2). This further supports that N RNA-binding is not required for phase separation
of HMPV proteins. However, further experiments are needed to confirm that the N
K171A/R186A mutations effectively block RNA-binding. Additionally, the HMPV
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N0-P and N K171A/R186A constructs should be expressed in cells alone or with
HMPV P to determine if IB-like structures form. These cellular results would be
beneficial in conjunction with the in vitro purified protein data for explaining phase
separation mechanisms.
Along with the HMPV N K171A/R186A mutant, future studies will analyze
other HMPV N constructs that possess mutations in the RNA-binding cleft. We are
particularly interested in analyzing these mutants since RNA plays a significant
role in phase separation (164, 171). The published structure of the HMPV N RNAbinding cleft was analyzed to select specific residues to mutate: K171A, R185A,
R186A, R189A, and R341A (47). These mutants will be tested in the in vitro system
and in cellular studies to determine their effects on viral replication and phase
separation. A minigenome assay will be used to determine if these mutations block
or inhibit replication. Immunofluorescence experiments will be utilized to assess
whether the mutants form IB-like structures with HMPV P. For the mutants that do
form IB-like structures, fluorescence recovery after photobleaching (FRAP)
analysis will be performed to analyze the internal contents of the compartments.
The FRAP results will be compared to the recovery observed for IB-like structures
formed by WT HMPV N and P.
The COVID-19 pandemic has generated an enormous amount of research
focused on understanding the infectious mechanisms of the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), and some studies have
highlighted the role of phase separation in the SARS-CoV-2 life cycle. SARS-CoV2 is a positive-strand RNA virus with a large genome of approximately 30
kilobases. It uses a multifunctional nucleoprotein (N) to package the genome into
new virions. Unlike the negative-strand viruses described throughout this
dissertation, SARS-CoV-2 does not have a separate P protein to act as a cofactor
for the polymerase. Instead, the SARS-CoV 2 N protein contains three IDRs and
is thought to facilitate viral RNA synthesis at early stages of infection. Several
reports, many of which are still preprints, have reported that SARS-CoV-2 N forms
condensates with viral RNA (172-176). This suggests that SARS-CoV-2 and other
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coronaviruses may utilize LLPS to enhance viral replication and packaging. These
findings support that viruses outside of the negative-strand RNA virus classification
may

have

also

evolved

mechanisms

to

generate

condensates

to

compartmentalize specific reactions.
Post-translational modification of the P protein
IDRs within proteins are particularly susceptible to post-translational
modifications because they lack secondary structure (177). In general, posttranslational modifications often act as switches to turn proteins on or off to
regulate cellular events. Post-translational modification of intrinsically disordered
proteins in liquid organelles provides another method by which cells can influence
the formation and dissolution of these structures. One type of post-translational
modification is phosphorylation of serine, threonine, and tyrosine residues. The
addition of a negatively charged phosphoryl group to an uncharged amino acid
may either promote or inhibit the formation of phase separated compartments
(177).
MeV P is phosphorylated at several sites, including S86 and S151 which
are located in IDRs. These two sites are phosphorylated by casein kinase 2, and
the phosphorylation status of the residues changes when MeV P binds to N (178,
179). Mutating the serine residues or inhibiting casein kinase II led to a decrease
in the size of IB-like compartments formed in cells, suggesting that phosphorylation
of MeV P affects structural aspects of IB formation (86). Additionally, the vesicular
stomatitis virus P protein has been shown to undergo phosphorylation events by
cellular kinases, leading to changes in transcriptional activity (180). In a SARSCoV-2 preprint, phosphorylation of the multifunctional N protein led to the formation
of liquid-like droplets with RNA, whereas unmodified N protein formed gel-like
droplets with RNA (181). This study hypothesized that unmodified SARS-CoV-2 N
is required for nucleocapsid assembly, whereas phosphorylated N protein phase
separates for viral genome processing. The HMPV P protein was analyzed by
mass spectrometry to show that it is phosphorylated at residues 106, 148, 157,
158, 168, 171, and 271 (92). Further studies of HMPV P phosphorylation will be
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important for understanding the role of these post-translational modifications in
replication and IB regulation.
Identifying IB-resident proteins
Although some viral and host factors within IBs have been discovered,
further identification of IB components may help elucidate the mechanisms that
govern IB formation and maturation. However, purification of IBs from infected cells
presents challenges since IBs have a liquid nature and lack a physical barrier.
Recent work described the purification of liquid-like granules containing FUS, a
DNA- and RNA-binding protein implicated in ALS (182). FUS contains a low
complexity domain that allows it to form multivalent interactions to mediate LLPS
(183). Since HMPV and other negative-strand RNA viruses form liquid organelles
similar to FUS, this purification procedure may be beneficial for analyzing the
internal contents of IBs to identify protein interactions that mediate LLPS. Viral IBs
appear to mature throughout infection, so IBs would need to be purified at different
time points and analyzed separately to fully understand the landscape of these
structures. Purified IBs would be subjected to mass spectrometry and proteomic
analysis to identify proteins that reside in IBs. These studies would provide critical
information for understanding which proteins are recruited to IBs at different times
during infection. Additional analysis would be needed to determine the proteinprotein interactions that lead to IB recruitment. The different aspects of liquid
organelles described here highlight some of the interesting research questions
which must be addressed to benefit our fight against negative-strand RNA viruses
that cause human disease.
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Figure 5.1. HMPV P and N-RNA/P liquid droplets contain round, dimple-like
regions. Heparin purified HMPV P (15 µM) was tested alone or with HMPV N-RNA
(15 µM) in a droplet assay. DIC microscopy images were acquired with a 60X
objective on a Nikon Eclipse E600. The scale bar is 10 µm.
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Figure 5.2. HMPV P recruits N K171A/R186A to liquid droplets. HMPV N
K171A/R186A (15 µM) was mixed with anion exchange purified HMPV P (15 µM)
in a droplet assay. DIC images were acquired using a 60X objective on a Nikon
Eclipse E600. The scale bar is 10 µm.
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APPENDIX

List of abbreviations
ALS

Amyotrophic lateral sclerosis

CedPV

Cedar virus

CT

C-terminal cytoplasmic tail

CTD

C-terminal domain

ER

Endoplasmic reticulum

F

Fusion protein

FAK

Focal adhesion kinase

FP

Fusion peptide

FRAP

Fluorescence recovery after photobleaching

G

Attachment protein

HeV

Hendra virus

HMPV

Human metapneumovirus

HRA/HRB

Heptad repeat A/B

IB

Inclusion body

IBAG

Inclusion body-associated granule

IDR

Intrinsically disordered region

IMAC

Immobilized metal affinity chromatography

L

Large polymerase protein

LLPS

Liquid-liquid phase separation

MeV

Measles virus
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M

Matrix protein

M2-1/M2-2

Matrix-2 proteins

N0

Monomeric RNA-free nucleoprotein

NiV

Nipah virus

N-RNA

RNA-bound nucleoprotein rings

NTD

N-terminal domain

P

Phosphoprotein

P-bodies

Processing bodies

PIV5

Parainfluenza virus 5

RABV

Rabies virus

RSV

Respiratory syncytial virus

SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2

SH

Small hydrophobic protein

TMD

Transmembrane domain

VSV

Vesicular stomatitis virus

WT

Wild type
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